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Title of Dissertation: Drug Delivery Strategies using Light Sensitive Molecules 
By Martin Michael Dcona, M.Sc 
A thesis submitted in partial fulfillment of the requirements for the degree Doctor of 
Philosophy, in Chemistry at Virginia Commonwealth University, 2012.  
Major Director: Matthew C. T. Hartman, Ph.D., Assistant Professor, Dept. of 
Chemistry, VCU 
Cancer remains one of the most dreaded diseases due to inevitable suffering and possible 
fatality. Only cardiac disease has caused more deaths than cancer
1
. Present day cancer 
treatment involves radiation, surgery or chemotherapy. In chemotherapy, an anti-tumoral 
drug is used to treat the tumor either by killing or stalling the growth of the tumor cells. 
In certain types of cancer, for e.g. metastatic breast cancer, the first line of therapy is 
often chemotherapy. But the inability of current clinically approved drugs to selectively 
target tumor cells, ultimately results in side effects. To reduce these side effects, prodrug 
therapies have been developed. A prodrug is defined as a drug molecule inactivated by a 
temporary cap or carrier, subsequently removed by an external intra or extracellular 
stimulus. Several prodrug strategies such as ADEPT (Antibody–Directed Enzyme 
Prodrug Therapy)
 2
 have been tested in clinical trials but have thus far met with limited 
success.  
In the wake of these limitations, development of photo-activatable prodrugs may be 
particularly desirable for minimizing the adverse side effects associated with current 
xvii 
 
cancer chemotherapeutics. Photodynamic therapy (PDT)
3
 is a light dependent tumor 
treatment modality that has existed for many years. PDT involves a photosensitizer which 
is administered to the patient and later activated using the light of wavelengths between 
650-800 nm. The activated photosensitizer creates singlet oxygen, which acts as 
cytotoxic agent to the tumor cells. But this approach has several drawbacks including 
slow uptake of the photosensitizer by the tumor cells and the dependence on molecular 
oxygen that is not always present at even moderate levels in the tumor tissues.  
To address these limitations of PDT, we developed a new prodrug concept called 
‘Photocaged Permeability’ in our first project, and demonstrated drug delivery using this 
approach 
4
. The basis of this concept is that, by attaching a hydrophilic molecule to the 
drug via a photosensitive linker, the permeability of the drug could be restrained. But the 
drug could be released at the site of the tumor after irradiating with UV light. To achieve 
this goal, we designed and synthesized a photosensitive drug conjugate that was 
comprised of doxorubicin attached to a negatively charged, cell impermeable molecule, 
EDANS (5-((2-Aminoethyl) amino) naphthalein-1-sulfonic acid) via a photosensitive 
nitroveratryl linker. Later, we performed MTT (cell viability) assays using esophageal 
adenocarcinoma (JH-EsoAd1) cells to determine the efficiency of our drug conjugate to 
induce cell death. As expected our drug conjugate was able to induce cell death, but only 
in presence of light. But in the dark, the cells remained unaffected. Also, we did several 
control studies to substantiate the fact that the cell death was actually due to drug release 
but not due to light or other entities. Further, we performed FACS (Fluorescence Assisted 
Cell Sorting) and confocal assays to show that in dark, the drug conjugate did not 
xviii 
 
permeate cells. But upon irradiation with UV light, the drug was released from the 
conjugate, permeated the cells and induced cell death.  
A weakness of the above mentioned approach is that the drug is “decaged” or photo-
released from the conjugates only under UV light; which cannot be translated to 
physiological conditions. This is because the UV light cannot penetrate deeper than 5 mm 
into the human skin
5
. As a result, tumor cells that are deeply embedded in the human 
body cannot be treated using these approaches. To address this problem, Near Infrared 
(NIR) light could be used as it penetrates deeper than UV. Recently, several groups have 
reported using Upconverting Nanoparticles (UCNP)
 6 
for the purpose of drug activation. 
The basis of this phenomenon is that the incidence of NIR light on these particles initiates 
multi-photon processes, eventually emitting UV/VIS wavelengths. The advantage of the 
NIR is that it deeply penetrates into the human skin. In our latest project, we have 
designed a drug conjugate that would be attached to UCNPs. We envision that after 
grafting the drug conjugate onto the nanoparticles and irradiating it with NIR drug release 
will occur as a result of upconversion.  
The above two systems describes novel methodologies for controlled release of the drug. 
To further improve the efficacy of the drug action, we designed new photosensitive 
systems based on the concept of targeted drug delivery. Targeted drug delivery is a 
treatment methodology in which the modified chemotherapeutic drug with higher tumor 
affinity could be concentrated in the tumor tissues. In certain cases, the receptors of 
tumor cells are targeted for the purpose of therapy. Receptors are cell surface proteins 
that are expressed on their plasma membrane. A select few of them such as Folic Acid 
Receptor (FAR) 
7
 and PSMA (Prostate Specific Membrane Antigen) 
8
are overexpressed 
xix 
 
in malignant cells. In our new designs, we attached folic acid
9
 and urea based (DUPA) 
ligand
10
, which were previously reported to bind to FAR and PSMA receptors 
respectively. Cell studies are currently underway to determine the specificity of these 
drug conjugates in targeting tumor cells.  
Once we demonstrate the above drug delivery strategies in vitro and later in vivo, we will 
have established novel drug delivery systems that could potentially be applied towards 
chemotherapeutic treatment.  
References:  
1. http://www.cdc.gov/nchs/fastats/lcod.htm  
2. I. Niculescu-Duvaz, C.J. Springer. Antibody-directed enzyme prodrug therapy 
(ADEPT): a review Adv. Drug Deliv. Rev. 26, 151–172  
3. I. J. Macdonald and T. J. Dougherty. Basic principles of photodynamic therapy. J. 
Porphyrins Phthalocyanines 2001, 5, 105–129  
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CHAPTER 1:  CANCER AND CHEMOTHERAPY 
  
2 
 
1.1 Cancer 
Cancer remains one of the most dreaded diseases in the modern world. According to 
the latest statistics
1
, it remains the second highest cause of deaths that occur in the 
United States of America. The most common form of cancer in the male population is 
prostate cancer and in females, breast cancer. The disease is usually characterized by 
uncontrolled growth of cells that are naturally supposed to undergo apoptosis. But 
instead they proliferate and form tumors. In some cases, these abnormal cells 
metastasize and ultimately result in the death of a patient. The causes of cancer are 
usually attributed to external factors such as tobacco, radiation etc. or internal factors 
such as mutation, obesity etc. In all cases, there are consequential formations of 
abnormal cells. Common treatments for cancer include radiation therapy, surgery, 
chemotherapy etc.  
Chemotherapy 
Chemotherapy is a common methodology in cancer treatment. It usually involves 
antineoplastic drugs that are administered either singly or in combination. These 
drugs act on the abnormal cells and kill them typically by interfering with DNA 
synthesis
2
. A key issue associated with conventional chemotherapy is unfavorable 
bio-distribution of the drug and low levels of drug accumulation in the tumor tissue.   
As a result current chemotherapies exhibit inevitable side effects. 
1.2 Passive Targeted Drug Delivery 
To regulate the side effects caused due to non-specific activity of the drug conjugate, 
targeted drug delivery was developed. Targeted drug delivery refers to drug 
accumulation at a particular site, specifically within the tumors via receptors or 
3 
 
growth factors. In this section, a few examples of targeted drug delivery will be 
illustrated. 
Principles of drug delivery: 
Drug transportation to a tumor site relies on two basic targeting approaches. They are 
active and passive targeting.  
Passive Targeting and ‘Enhanced Permeation and Retention’ effect 
Passive targeting refers to drug accumulation in tumor tissues with leaky 
vasculatures. The endothelium is made of tightly packed cells. But in case of tumors, 
the tight packing of cells is disrupted, which eventually develops leaky vasculature 
which can allow small and large molecules easily to penetrate through the tissues (Fig 
1.2.1). Hence, this characteristic of tumor tissues was used to improve the 
permeability and concentration of the drug molecules in chemotherapy. This 
approach is referred to as Enhanced Permeation and Retention (EPR) effect
3
. Drug 
delivery via conventionally used liposomes is an example of passive targeting. 
Liposome mediated drug delivery 
Liposomes are a micro-particulate assembly of amphiphilic molecules that are 
spontaneously formed when lipids are hydrated in aqueous media
4
. The liposomes are 
used to encapsulate drug molecules and hence, they are used as drug carriers. (Fig. 
1.2.2) 
4 
 
  
Fig. 1.2.1 Passive Targeting: Graphical representation of normal and tumor tissue with 
respect to vascular permeability of small and large drug molecules 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Fig. 1.2.2 Drug encapsulated in liposomes. 
Drug 
Lipid Bilayer 
 
Cell surface receptor 
binding small molecule, 
antibody and peptide 
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In ‘passive’ liposome mediated drug delivery, a therapeutic molecule that is either 
hydrophilic or hydrophobic is encapsulated in a lipid bilayer with aqueous phase. 
This particle when administered to the patient will penetrate leaky tumor vasculature 
due to the EPR effect. Examples of passive targeted liposomes that are currently used 
in chemotherapy are Doxil
5
, Myocet
6 
etc. But, passive targeting of liposomes suffers 
from a major disadvantage of non-specific localization
7
. To address this issue, cell 
surface receptor binding ligands were attached to the surface of liposome for 
enhanced specificity leading to ‘active’ liposome mediated drug delivery. 
1.3. Active Targeting: Targeting receptors on tumor cells 
1. 3.  1. Introduction: 
A major challenge with current chemotherapy is off-target toxicity which leads to 
significant side effects. Here, we highlight the importance of targeted drug delivery and 
describe several targeted delivery strategies.   
Targeted drug delivery: 
To reduce off-target effects of anticancer drugs, targeted drug delivery has been 
developed. This type of drug administration refers to predominant drug accumulation in 
tumor cells via usage of a homing ligand or a peptide that binds specifically to a receptor 
expressed primarily on cancer cells.  
Human cell surface receptors are proteins that are predominantly expressed on plasma 
membranes. These receptors exhibit high affinity towards certain types of vitamins and 
nutrients required for the proper growth of cells. But in malignant cells, these receptors 
7 
 
are overexpressed due to abnormal functioning of cellular mechanisms. And when these 
ligands are modified by conjugating a therapeutic drug, they enhance the concentration of 
the non-selective drug specifically in the tumor cells, limiting off target side effects.  As a 
result these receptors are becoming increasingly popular for the purpose of 
chemotherapy
11
 and are also being used towards imaging
12
.  
Targeted delivery often employs a ligand that binds to the receptors that are 
overexpressed on the cell surface, with high specificity and affinity. Such targeting 
ligands include folic acid
13
, LHRH
14
 etc. There are also certain small molecular weight 
inhibitors that bind to overexpressed cell surface proteins such as 2-PMPA
12
.  In this 
section, we highlight two different ligands and their targets that embody all the above 
features. Specifically, we will be describing folate receptor and Prostate Specific 
Membrane Antigen (PSMA) receptor mediated drug delivery. 
1. 3. 2. Receptor mediated Endocytosis: 
Endocytosis refers to a pathway by which a molecule is carried into cells via membrane 
invagination and internalization
15
. Receptor mediated endocytosis occurs via cell surface 
proteins that interact with the exogenous ligands and mediate their passage into the cells. 
Many examples of cell surface proteins exist which are overexpressed in tumors. Some of 
the best established include Folate Receptors (FR) 
11
, PSMA
16
 and Growth Factor 
Receptors such as vascular endothelial growth factor (VEGF) Receptors
17
. 
Mechanisms of Endocytosis: 
There are several types of endocytosis pathways
18
 which include: Clathrin-mediated 
endocytosis, non-clathrin or caveolae mediated endocytosis, macropinocytosis and 
8 
 
phagocytosis
15
. But here, we will focus on the first two as they are of primary concern in 
our work.  
Clathrin Mediated Endocytosis (CME): 
CME is the most common form of endocytosis and is responsible for internalization of 
ligands, antigens etc. Clathrin is a protein that plays an important role in formation of 
vesicles
19
. The internalization of the incoming ligand takes place by recruitment of 
soluble clathrin from the cytoplasm to the cell membrane. The multi-protein interactions 
then result in formation of clathrin coated pits that bud from the cellular membrane. 
These pits then internalize forming vesicles that encapsulate the incoming ligand or 
antibody via receptor.  Later these encapsulated vesicles are pinched-off from the plasma 
membrane and continue to move into cytoplasm to form an early endosome and then late 
endosomes. Finally, these late endosomes merge into lysosomes that contain low pH 
enzymes. At this point, the ligand binding receptor either gets destroyed or recycles back 
to the cell surface for additional rounds of internalization (Fig. 1). An example of clathrin 
mediated endocytosis is the internalization of PSMA
16
. 
Caveolae mediated or Clathrin independent Endocytosis (CIE): 
In caveolae mediated endocytosis, the buds that are generated from the plasma membrane 
are not coated with clathrin; hence it is most commonly referred to as Clathrin 
independent endocytosis. Caveolae are cholesterol- and glycosphingolipid-rich flask 
shaped invaginations of the plasma membrane that are abundant in vascular 
endotheliums. The mechanism of CIE is similar to the CME, wherein multi-protein 
interaction results in formation of a cave like structure. These “small caves” shaped pits 
9 
 
(hence the name), are responsible for endocytosis of certain ligands such as folic acid
13
, 
and several nonenveloped viruses
19
. 
10 
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1. 3. 3. Folate receptor mediated drug delivery 
Folic acid (FA), also known as vitamin B9, is taken up by cells and is metabolized to 
tetrahydrofolate and other reduced FA derivatives which are the substrates for many 
important enzymes in the cell
20
. FA is needed to carry one carbon for methylation 
reactions and de novo synthesis of nucleotide bases. Therefore, it is essential to the 
viability of proliferating cells
11
. 
Cellular uptake of Folic acid 
In the human body, two independent and mechanistically different systems mediate the 
cellular uptake of FA.  
 The Reduced Folate Carrier (RFC) is a low affinity (Kd ~ 10
-5
 M), high-capacity 
membrane-spanning anion transport protein that delivers reduced FAs across the 
plasma membrane in a bidirectional fashion
21
. 
 The Folate Receptor (FR) is a high affinity (Kd ~ 10
-10
 M), single chain FA-
binding protein which internalizes FA through active-receptor mediated 
endocytosis
13
. 
Isoforms of FRs 
There are three known isoforms of the folate receptor. Specifically, FR-α and FR-β are 
the isoforms that are associated with cell membrane and, FR-γ and its truncated cogener 
FR-γ’, are the secreted from.13 In healthy human tissue, FR-α is limited to the apical 
(externally-facing) membrane of the polarized epithelial cells, thus it is not accessible to 
folates in the blood stream. For this very reason, normal tissues are not affected by the 
folate receptor mediated therapy, making this approach very selective
22
. Whereas, in 
12 
 
malignant cells, the FR (α) isoforms of the folate receptor are highly overexpressed23 and 
hence serve to target drug delivery to those cells. 
Folic acid conjugates: 
Folic acid (Fig. 1.3. 2) has two components, pteroic acid and L-glutamic acid which are 
coupled via a peptide bond. Conjugation of molecules to FA at its γ-carboxy moiety on 
glutamic acid may influence its binding affinity towards FR. However, it was found in 
many cases, that this conjugation does not affect the Kd value significantly, and thus this 
site is commonly used for derivatization.  
An example of the effectiveness of FA targeting can be demonstrated by examining the 
bio-distribution of 
111
In –diethylene triamine pentaacetic acid (DTPA) - FA, an imaging 
agent in patients that are tumor free and those that possess FR-positive tumors (Fig 3). In 
a healthy individual, accumulation of the conjugate is only seen in the kidneys. But in the 
patient with the metastasizing cancer, the imaging probe binds to the tissues that 
overexpress the FR and thus FR positive tumors are evident throughout the body, as seen 
in scintigraphic images
24
. 
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Fig. 1.3.2. Chemical structure of folic acid 
  
Pteroic acid L-Glutamic acid 
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Fig. 1. 3. 3. Chemical structure of 
111
In–DTPA–folate used in whole body scintigraphic 
images cancer patient. The uptake of this molecule in the cancer patient is seen only in 
the malignant tissue  
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Folate receptor mediated endocytosis of drug conjugate: 
As mentioned previously, folic acid and folate conjugates undergo FR mediated 
endocytosis.  The events that occur during folate receptor-mediated endocytosis are 
illustrated in Fig 1. 3. 4.  
Mechanism: 
At first exogenous folic acid binds to receptors that are continuously recycling and are 
exhibited on the cell surface. After binding, the plasma membrane begins to invaginate 
until a distinct vesicle called an early endosome (shown in yellow) forms within the cells. 
These vesicles with ligand and receptor may interact with golgi apparatus, which are then 
transported to late endosomes. At this point, the pH value in these vesicles lowers to ~ 5 
through the action of proton pumps, after which the ligand dissociates from the receptor. 
After this, one of the below listed events may occur
25
.  
 The ligand and the receptor may end up in the lysosomes for destruction26 
 The ligand may be directed to lysosome for destruction whereas the receptor may 
recycle back to cell surface 
 The ligand can leak into the cytosol (this is the case with folic acid and its 
receptor recycling) 
 Both ligand and receptor recycle back to the cell surface 
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Fig. 1. 3. 4. Folate receptor mediated endocytosis of folic acid-drug conjugate  
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Example of Folic acid-drug conjugate used in clinical trials: 
 
 
 
 
 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 1. 3. 5. Vintafolide (EC145) is a vinblastine conjugate linked to folic acid (JCO, 2012, 
4011-4016) 
EC145 
Folic acid 
Vinblastine 
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1. 3. 4. PSMA binding ligands 
Rationale   
PSMA is highly homologous to the enzymes that are found in the central nervous system 
(CNS) and proximal small intestines
27
. One of the enzymes in the CNS is the 
neuropeptidase NAALDase, which releases the neurotransmitter glutamate which were 
found to be responsible in number of neurological disorders
28
. Hence to reduce these 
disorders NAALDase/GCP II inhibitors were developed; which were also found to be 
potential PSMA inhibitors. 
Phosphonate based inhibitors: 
One of the first reports of the NAALDase inhibitor was published by Jackson et al 
29
 
wherein they reported synthesis of phosphonate and phosphinate inhibitors. In this work 
they found that 2–(phosphonomethyl)-pentanedioic acid (2-PMPA) had over 1000 times 
more potency (Ki= 0.275 nM) than other conventional inhibitors
30, 31
 However, 2-PMPA 
suffers from a poor pharmacokinetic profile due to its high polarity, so its value as a 
therapeutic drug has been limited.  
Urea based inhibitors: 
Later, Kozikowski et al
32
 reported urea based inhibitors, based on the mechanism of the 
enzyme as well as modeling studies. These inhibitors comprised of two amino acids that 
are joined through a urea bond. Unlike 2-PMPA, the synthesis of these molecules is 
easier and could be modified to attach a drug or an imaging agent. Also the binding 
efficiency (Ki= 0.8-8.0 nM) of these molecules is almost equal to that of 2-PMPA. 
19 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. 3. 6: Phosphonate and urea based inhibitors with their respective Ki values. 
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Applications of PSMA binding ligands  
PSMA in Imaging: 
Recently, several groups have demonstrated successful usage of PSMA inhibitors for 
imaging in experimental models of prostate cancer
12, 16
. This was done by conjugating 
radio-nuclides to the above discussed urea and phosphinate based inhibitors. A general 
example of an imaging molecule is shown in Fig. 1.3.6. 
 
  
Fig. 1. 3. 7: A general example of an imaging molecule for PSMA imaging 
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PSMA in Therapy: 
PSMA has served as an ideal target for several monoclonal antibodies that are highly 
specific in treating prostate cancer. But the usage of the PSMA binding ligands for the 
purpose of treatment is relatively new and has not yet been explored in clinical trials. One 
of the first examples of application of targeted therapy in vivo was demonstrated by Phil 
Low and group, wherein they were able to demonstrate the specificity of the urea based 
ligands towards PSMA for the purpose of drug delivery
16
. 
1.3.5 Antibody Directed Enzyme Prodrug Therapy (ADEPT): 
A final example of active targeting is ADEPT
9
.  In this methodology an enzyme (E) is 
conjugated to an anti-tumor antibody and is administered to the patient. The enzyme-
antibody conjugate recognizes the tumor specific-antigen and hence localizes inside the 
tumor tissues. Later, a prodrug is administered to the patient, which is converted to an 
active cytotoxic drug by the enzyme that is now present only inside the tumor (Fig. 
1.3.8)
10
.  
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Fig. 1.3.8 Graphical description of ADEPT 
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1. 3. 6. Disadvantages of receptor targeted drug delivery: 
Traditional tumor therapies suffer from non-specificity of drug retention and action, 
resulting in toxicity to healthy tissues. In wake of this limitation, the advantage of 
targeting receptors to be able to deliver the anti-cancer drug specifically to the tumor cells 
has opened a new avenue to develop novel targeted therapeutics with reduced side 
effects. As mentioned many times in this chapter, receptor mediated drug delivery 
employs a ligand conjugated to a drug molecule, which then selectively binds to tumor 
receptors, undergoes endocytosis and eventually releases the cytotoxic drug.   However, 
the therapeutic application of receptor-drug conjugates in biological environments suffers 
from some key problems. Firstly, the endocytic pathways transport only a fraction of the 
drug conjugates into cells. As a result, the optimum levels of drug concentration required 
for cell death may not always be present. The other limitation is endosomal entrapment of 
the drug conjugate. Once internalized, the drug conjugate can be trapped inside the 
endosomes, resulting in accumulation of latent drug conjugate. This is more common if 
the drug conjugates are membrane impermeable.  
Alternative to the existing drug delivery system: 
 In wake these limitations, a modified ligand-drug conjugate is essential that can 
overcome most of the above drawbacks. As mentioned in the previous section, light 
sensitive molecules have been previously applied toward drug delivery. Hence, to allow 
the easy endosomal escape of the drug, it is desirable to design an easily activatable drug 
conjugate. In chapter 3, we report two such drug conjugates combining the merits of 
targeted drug delivery and photocaged drug delivery. 
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Chapter 1.4: Photodynamic Therapy: The emergence of light based therapy 
 
1.4.1 Introduction 
The usage of light for therapeutic purposes has seen a great surge since the introduction 
of Photodynamic Therapy (PDT) as a non-invasive, yet effective treatment modality. In 
Photodynamic therapy a combination of low energy light, photosensitizer and tissue 
oxygen is employed to induce cell death. The success of this treatment depends on 
generation of singlet oxygen, which is the main cause of cytotoxicity. PDT has been 
employed in many malignant diseases with some success
33
. 
In this section, the mechanism of PDT and disadvantages associated with this treatment 
modality will be discussed.  
1.4.2. Mechanism of PDT:  
In PDT, a porphyrin based unit called Photosensitizer (PS) is employed in conjunction 
with light of wavelength between 600-800 nm. In clinical treatment, PDT is two-step 
process. Firstly, a PS is administered to the patient either intravenously or topically at the 
site of tumor. After a certain period of time, the photosensitizer is allowed to clear from 
the body, but retained in tumor tissues, the skin and endothelial systems
34
. In the second 
step, the tumor is irradiated with light of an appropriate wavelength (depends on PS used) 
usually with laser or LED light source. As a result, the PS gets activated to form P* (high 
energy PS), which eventually results in number of photochemical reactions. These 
reactions result in generation of cytotoxic ROS (reactive oxygen species), predominantly 
singlet oxygen (
1
O2) from oxygen in the environment of tissues. This specie oxidizes the 
bio-molecules in the cells eventually leading to cell death
35
. 
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Step1: Photosensitizer 
(PS) is injected to the 
patient 
Time lapse 
Fig.1.4.1 Mechanism of Photodynamic Therapy 
Step 2: After certain 
time interval, PS 
accumulates in tumor; 
later irradiated with 
λ=650-800 nm light 
Tumor cells are killed 
due to generation of 
singlet oxygen species: 
Seen here is the 
decreased tumor 
volume 
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1.4.3 Photosensitizer: 
The efficiency of PDT is dependent on three important components. 1) Photosensitizer 2) 
Intensity and location of light treatment 3) Molecular oxygen.  
The majority of PSs that are currently being used in research and clinical trials are 
derivatives of porphyrin units. These cyclic units have good photophysical and 
photosensitizing properties and are able to selectively accumulate in tumor tissues
33
. The 
preferential retention of a PS in tumor is attributed to presence of leaky vasculature
34
. PSs 
can be modified by attaching ligand
36
, antibody
37
 or peptides
38
 to increase their 
concentration in tumors. 
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Fig. 1.4. 2. Chemical structures of some clinically used photosensitizers 
 
 
28 
 
1.4. 4 Limitations of PDT: 
Although PDT has great potential as a cancer treatment modality, there are several 
drawbacks that limit its applicability in clinical therapy. One of them is unpredictable 
light to drug administration times caused by slow uptake/ metabolism of the 
photosensitizers 
39
. One of the major drawbacks of PDT is that the most commonly used 
photosensitizers absorb light between 630-690 nm
40
 which has very low tissue 
penetrability. This is due to the fact that there is absorption and scattering of the incident 
light. The other major drawback of this therapy is dependence on molecular oxygen, 
which is required to create singlet oxygen in presence of PS. Tumor tissues don’t always 
have moderate levels of oxygen in their surroundings, due to which this treatment 
modality may be unsuccessful
41
.  
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1.5. Photo-responsive Molecules: Focus on O-nitroveratryl photocage 
Introduction 
Recently, light mediated biological processes have gained great attention due to the fact 
that light offers a high level of spatial and temporal control. In this section, we illustrate 
two different types of light sensitive molecules that are currently being used for certain 
biological and drug delivery systems.  
1.5.1. Photoswitches: 
Photoswitches belong to the class of photo-responsive molecules that undergo 
conformational change under the irradiation of light
42
. Most of the currently used 
photoswitches are responsive towards UV light and undergo structural isomerization as a 
result of multi-electron phenomena. Several examples of photoswitches are 
azobenzenes
4
, spiropyran/merocyanine
43
, fulgides
42
 and hemothioindigo
44
 chromophores. 
(Fig.1.5.1). Azobenzenes
45
 are the most common form of photoswitches that have been 
used for many applications in materials
46
 and biological chemistry
47
. Their usefulness 
stems from the fact that they undergo reversible photoswitching from trans to cis of the 
N=N, under UVA light, specifically ~360 nm and then undergo thermal relaxation, in 
dark or at 450 nm. The time required for thermal relaxation depends on the modification 
on the azobenzene or on the biomolecule to which it is conjugated
48
. 
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Fig. 1.5.1 Photoswitches: a) Azobenzenes b) Spiropyrans c) Hemothioindigo d) Fulgides 
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1.5.2. Photocages: 
Introduction 
Photosensitive protecting groups are often referred to as “photocaging” molecules or 
simply “photocages”.  Photocaging refers to a phenomenon wherein the activity of a 
certain molecule is blocked using a photosensitive linker that can be removed at a later 
time when this molecule is irradiated with light of an appropriate wavelength; thus, 
restoring its activity
42, 49. This phenomenon is called “decaging”. One the first examples 
of application of photocages dates back to 1978, when Kaplan et al
50
 used photocaged 
caged ATP compounds for studying Na/K pump. Since then many groups
51-53
 have 
installed photocaging groups onto biomolecules to modulate their activities with spatial 
and temporal control. 
Examples of photocaging molecules: 
Many photocaging molecules have been developed for a number of biologically relevant 
functional groups such as phosphates
54
, amines
55
 and thiols
56
. These molecules undergo 
rapid irreversible photolysis under light of the appropriate wavelength, but are stable in 
dark conditions. In this section, we describe three of the most commonly used photocage 
molecules that are activated at different wavelengths and describe their applicability in 
current research.  
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O-Nitrobenzyl derivative 
Coumarinyl derivative 
Cob-4 derivative 
Fig: 1.5.2 Photocage Molecules 
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1.5.3. O-nitrobenzyl caging group: 
One of the most commonly used photocage molecules is the o-nitrobenzyl (ONB)
 57
 and 
its derivatives (1.11-1.14).  The reason for vast applicability of these molecules is that 
they can be easily installed on any functional group including amines, thiols, alcohols or 
carboxylates. As a result, they have been applied to nucleic acids
58
, proteins
59
, peptides
60
 
and small molecules
61
. These molecules could be activated at wavelengths ranging from 
315-400 nm depending on the functional groups on the core molecule
57
. In addition, the 
release kinetics of these molecules are extremely fast in comparison to any other caging 
units. These molecules undergo photolysis at a rate of micro to milliseconds and give 
quantitative yields. 
But there are also several key disadvantages of using the ONB group as a photocage. 
Primarily, these molecules are decaged only in presence of near UV, which might be 
detrimental toward cells
62
, especially in cases where longer exposure of light is needed 
for performing the in vitro assays. Although many findings indicate that ONB could be 
applied toward chemotherapy, the major drawback of this approach is the range of 
wavelength that is being employed for decaging is less penetrating rendering this 
approach ineligible for in vivo studies. 
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Mechanism of deprotection of ONB
63
: 
Deprotection of ONB occurs under UV light. The reaction begins with the creation of 
excited state singlet radicals on oxygen and nitrogen of the ‘nitro’ functional group. The 
reaction then proceeds with 1, 5 transfer of hydrogen from carbon to oxygen, a Norrish 
type II process which is promoted by the greater strength of the O-H bond compared to 
the C-H bond, to give a  Z-nitronic acid intermediate.  Later the –OH attacks the methide 
to form an unstable five membered ring. Then charge transfer from oxygen results in 
formation of nitroketone or nitrosoaldehyde depending on the initial derivative of ONB 
and release of the photocaged molecule (X) (Fig. 1.5.3). 
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X= Biomolecule/ 
Drug 
Fig. 1.5.3: Mechanism of photo release from ONB caging unit 
36 
 
Examples of ONB caged compounds: 
In this section, certain representative examples that use ONB as a photocage for different 
molecules are illustrated.    
Photocaged Nucleotides: 
Deiters and group recently demonstrated an example of ONB derivatized, caged 
oligonucleotides (Fig. 1.5.4 a). Specifically, they caged thymidine nucleotides which are 
part of Triplex Forming Oligonucleotides (TFO) that help to regulate gene expression by 
inhibiting transcription. Due to caging, the formation of TFO: DNA triplex formation is 
blocked, hence rendering the TFO inactive. But under UV, thymidine nucleotides are 
decaged hence leading to the inhibition of transcription
58
. 
Photocaged Proteins 
Schultz and coworkers reported the usage of ONB in a photocaged tyrosine amino acid 
(Fig. 1.5.4 b), which was genetically encoded in E. coli. Incorporation of this caged 
molecule into a cytoplasmic enzyme, β-galactosidase; rendered it inactive. But under the 
irradiation of UV light, the ONB group was removed, which restored the activity of the 
molecules
59
.  
Photocaged Small Molecules        
Recently, Mascarenas and group reported the ONB derivatized nucleic acid stains such as 
ethidium bromide (Fig. 1.5.4 c) and DAPI. Using these caged molecules, they were able 
to demonstrate their inability to selectively bind DNA molecules. But under the 
37 
 
irradiation of UV light, the binding abilities were restored and were able to stain living 
cells and retinal tissues
61
.  
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 1.5.4: Examples of ONB caged molecules 
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1.5.4. Coumarin caging group 
Coumarin derivatives are less commonly used caging molecules but their application as a 
photocage has several key advantages. One of the most important advantages of this 
molecule over ONB is that it is activated in light of wavelength above 400 nm. This 
wavelength is not as damaging to the biomolecules as is UV. In addition, coumarinyl 
derivatives are fluorescent in nature to an extent. But when they undergo 
photoconversion the fluorescence of the molecule can be enhanced up to 200 fold
64
.  
Example of coumarin caged compounds 
Wiesner and coworkers
65
 used a coumarinyl methyl ester for caging cyclic nucleotides to 
study spatiotemporal dynamics of nucleotide dependent processes using one photon and 
two photon processes. Using this caged cNMPs, the authors were able to demonstrate 
spatial and time dependent control over cNMP triggered processes.   
  
Fig. 1.5.5: Example of photo release of cNMP from coumarin caged unit 
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 1.5.5. Cob-4 cage molecule 
Very recently, Lawrence and coworkers introduced a photocage (1.18) that could be 
cleaved in the range of 560 nm. In this seminal work, they reported vitamin B12 (cob-4) 
as a photocage and described its application towards site selective photodecaging at 
higher wavelengths which were never described previously. Specifically, cob-4 along 
with O-nitrobenzyl and coumarin units--each conjugated to different fluorescent 
molecules--were incubated with cells and irradiated at different wavelengths (Figure 
1.5.6) that are specific for the different photo-protecting groups
66
. 
 
 
 
 
Coumarin 
Cob-4 
O-Nitrobenzyl 
 
560 
nm 
 
 440 
nm 
Coumarin 
O-Nitrobenzyl 
O-Nitrobenzyl 
 
1.5. 6. Wavelength selective photolysis of cob-4, coumarin and ortho –nitro benzyl units 
360 nm 
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Abstract:  
Light is used to release a drug from a cell impermeable small molecule, uncloaking its 
cytotoxic effect on cancer cells. 
2. 1. Introduction: 
Off-target toxicity plagues conventional cancer chemotherapy. One strategy to enhance 
selectivity of anti-cancer drugs involves unmasking the cytotoxicity of a molecule in the 
vicinity of the tumor.
1
 This type of activation can be mediated by enzymes,
2,3
 changes in 
pH,
4
 or exogenous factors such as temperature
5
 or light.
6–8
 
Light is an ideal external stimulus since it provides a broad range of adjustable 
parameters
9
 that can be optimized for biological compliance. Several approaches that use 
light for biomolecular activation have been reported.
10–15
 One established method to 
enable selectivity of drug action using light is photodynamic therapy (PDT). In 
PDT,
16,17
 light activation of a photosensitizer generates cytotoxic singlet oxygen killing 
only illuminated cells. PDT is currently used in several types of malignancies
16
 including 
skin, lung, esophageal, bladder, head and neck, and prostate cancer. A related strategy, 
photochemical internalization,
18,19
 also uses photosensitizers. In this case, the 
photosensitizers are used to release macromolecular cytotoxins from endosomes, 
enabling their entry into the cytosol. However, these approaches suffer from 
disadvantages,
20
 including unpredictable drug uptake rates, the limited diffusion and 
lifetime of 
1
O2, and the requirement for moderate levels of O2 which may not always be 
available in the tumor environment. 
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In this chapter, we report a new light-targeted drug delivery system, which operates 
independently of the creation of 
1
O2. The basis of the system is the attachment of a cell 
impermeable small molecule to a drug via a linker that can be removed in presence of 
light, allowing cellular entry (Figure 1). We call this new strategy photocaged 
permeability (PCP).
21
 
 
 
  
  Figure: 2.1. Photocaged permeability strategy for drug delivery 
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2. 2. Building blocks to design photocaged drug conjugate   
Hydrophilic moiety 
 
Drug 
Hydrophilic moiety Linker 
Drug 
Desirable characteristics of 
hydrophilic moiety 
 
 Cell impermeable 
Desirable characteristics of 
the linker 
 
 Light sensitive 
 Should have 
functional groups 
to hold drug and 
impermeable 
moiety 
Desirable characteristics of 
the drug 
 
 Cell permeable 
 Functional group 
for attachment 
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As mentioned before, we envisioned to synthesize a cell impermeable drug conjugate. 
For this purpose, we followed a stepwise procedure to gather the components that would 
be used to build a desirable drug conjugate.  
Drug: 
Doxorubicin, a clinically approved, cell-permeable, anticancer drug was chosen for this 
study because of its intrinsic fluorescence (λ ex/em=470/590) 
32
. 
Doxorubicin also can be easily modified and functionalized at the free amine group (Fig. 
2.2 a), which renders the molecule non-cytotoxic
33
. 
Photocleavable linker 
As mentioned earlier in chapter 1, we were able to acquire the commercially available 
ONB derivatized photocleavable linker (Fig 2.2 d) that has two functional groups and 
could be modified to attach a drug and a hydrophilic moiety.  
Hydrophilic Moiety 
At the onset of this project, we sought a hydrophilic molecule that was reported to be cell  
impermeable.  Sulfonic acid groups are highly impermeable compared to other functional 
groups 
22
. Hence, we sought several molecules that had sulfonic acid functional group 
and concluded our search after finding APTS (8-Aminopyrene-1,3,6-trisulfonic acid) and 
EDANS ((5-((2-Aminoethyl)amino)naphthalene-1-sulfonic acid). 
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APTS: 
APTS (Fig 2.2 b) is green fluorescent dye often used to tag saccharides for separation and 
detection by capillary electrophoresis
27
. This molecule has three sulfonic acid functional 
groups in its structure. Hence, we first synthesized APTS 1 using a previously published 
report
28
, and then envisioned to synthesize the drug conjugate using the following 
synthetic schemes. 
Synthesis of APTS-Photocage conjugates using peptide coupling chemistry 
Our very first goal was to synthesize a conjugate of APTS-photocage using standard 
coupling chemistry (Scheme: 1).  
Route A: 
For this purpose, we first synthesized a succinimidyl ester of photocage molecule 
(activates the carbonyl bond), which was later made to react with APTS in presence of 
triethylamine (TEA) in the dark. The progress of reaction was monitored on TLC, which 
indicated that the reaction was not progressing to form expected product, but rather 
remained unreacted.  
Route B and Route C: 
Later, we ventured into other commonly used and efficient coupling mechanisms to form 
the conjugate. In Route B, we used DCC (N, N’-Dicyclohexylcarbodiimide) in the 
presence of TEA and HBTU in presence of TEA (acts similar to DCC). Even at higher 
temperatures, as indicated by TLC, these reactions did not proceed as expected. We 
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reasoned that the sulfonic acid functional groups highly deactivated the pyrene ring; as a 
result we were not able to proceed with coupling chemistry.  
    
Scheme 2.1: Synthesis of APTS-Photocage conjugate using coupling chemistry 
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Reductive Amination of APTS to attach linker: 
We then turned our attention to derivatize APTS using a reductive amination reaction 
which appeared to be facile based on a literature precedent
28
. 
 
Also, we figured that click chemistry is a viable option to attach APTS to our photocaged 
drug, as it is a high yielding and has previously been demonstrated
30
 to be a successful 
reaction to couple two different entities. Hence, we decided to prepare a derivatized 
APTS with an azide analog such that it could undergo click chemistry. 
Synthesis of APTS-Azide linker 
The synthesis as described in scheme 2.2 began with mono-tosylation of triethylene 
glycol 2.1 in the presence of tosyl chloride and triethylamine to give 2.2. This compound 
was treated with an excess of sodium azide to yield azido triethyleneglycol 2.3. Further, 
this white colored solid underwent Swern Oxidation, in presence of DMSO, oxalyl 
chloride and TEA, to give aldehyde 2.4. Finally, we stirred APTS 2.5 along with 2.4 in 
presence of sodium borohydride in methanol and anticipated formation of the imine 2.6. 
Unfortunately, this reaction did not proceed as analyzed by TLC and NMR.  
Thus, after multiple reaction trials and different reaction conditions, we discontinued the 
pursuit to synthesize a drug conjugate using APTS as hydrophilic moiety. We now sought 
a different molecule with a sulfonic acid functional group and with a more reactive alkyl 
amine.  
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Scheme: 2.2 Synthesis of APTS –linker. Reagents and conditions 
a) Tosyl chloride, Triethylamine (TEA), DMF at 0
o
C. b) Sodium azide at 50
o
C c) Oxalyl 
chloride, DMSO, TEA -78 
o
C. d) Sodium cyanoborohydride in MeOH 
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EDANS: 
EDANS is also a sulfonated dye (Fig 2.2 c) often used in conjunction with DABCYL as a 
FRET pair
29
. As seen in the figure, it has an ethylene diamine unit, which was easily 
modifiable and could be used for the coupling reaction. Hence, we proceeded with this 
molecule as the hydrophilic moiety.   
Syntheses of EDANS-Azide conjugate: 
At this point, we designed a scheme to synthesize an azide derivative of EDANS. We 
first acquired 4-azido benzoic acid (4) and then converted it to succinimidyl ester 
derivative (4) in presence of EDAC and NHS. Later, we attached EDANS to the activated 
ester molecule, to give the azide derivative of EDANS (5). The derivative was easily 
purified on flash column chromatography and was taken further towards click chemistry. 
 
 
Scheme 2.3 Synthesis of EDANS-Azide conjugate 
 a) NHS, EDAC, DMF. (b) EDANS, Et3N 
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Retrosynthetic analysis  
With our azide-containing sulfonic acid in hand we planned to assemble the desired 
photocaged Dox in the following manner.  We planned to attach the nitroveratryl 
compound to Dox via a carbamate linkage formed from a p-nitrophenyl carbonate.  
Secondly we planned to attach the sulfonated EDANS to the dox conjugate using click 
chemistry. 
 
 
 
 
 
Fig. 2.2. Strategy for synthesis of photocaged dox and EDANS conjugate. 
 
Doxorubicin Photocage linker Hydrophilic moiety 
Displacement of p-
nitrophenyl 
carbonate 
Click 
chemistry 
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Scheme 2.4: Synthesis of photocaged-cell impermeable drug conjugate. Reagents and conditions: (a) NHS, EDC-HCl; (b) 
propargylamine, Et3N; (c) bis p-nitrophenylcarbonate, Et3N; (d) doxorubicin-HCl, Et3N; (g) CuSO4·5H2O, sodium ascorbate, tris-
(benzyltriazolylmethyl)amine, DMSO: water (1:1) 
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2. 3. Synthesis of the photocaged-drug conjugate 
The synthesis (Scheme 1) began with commercially available nitroveratryl carboxylic 
acid (2.9). We first prepared the N-hydroxy succinimidyl ester 2.10 using N-hydroxy 
succinimide in presence of EDAC, in DMF. This off white-colored solid was taken to the 
next step without purification. This solid was solubilized in a solution of propargylamine 
in DMF, in presence of triethylamine base (TEA). The reaction yielded pale, white 
alkyne 2.11 in good yield after purification. The benzylic alcohol of 2.11 was reacted 
with bis-p-nitrophenol to form the activated mixed carbonate 2.12 in moderate yield.  The 
nitrophenyl group of 2.12 was displaced with doxorubicin to give Dox alkyne 2.13. 
Purity of the obtained solid was verified by HPLC (Fig. 2.4) 
Finally we coupled 2.8 and 2.13 (Scheme 2.4) solublized in 1:1 DMSO and water, in 
presence of CuSO4, sodium ascorbate and TBTA which gave 2.14, a red colored solution 
that was purified on RP-HPLC (Fig. 2.5) to give 41% of product. HRMS of the final 
compound is shown in Fig. 2.6. 
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HPLC Purity analysis of Photocaged Doxorubicin:  
 
Fig. 2.3: RP- HPLC analysis of (2.13) at using detection at 480 nm. The two 
diastereomers have retention times of 35.8 and 36.9 min 
 
 
 
 
% of B or 
acetonitrile 
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HPLC purity analysis of EDANS-DOX drug conjugate:  
 
 
Fig. 2.4: RP- HPLC analysis of EDANS-Dox (2.14), using absorbance at 480 nm. The 
two diastereomers have retention times of 31.25 and 32.28 min. 
  
% of B or 
acetonitrile 
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Fig. 2.5: HRMS (ESI) C63H63N8O22S of cell impermeable photocaged drug conjugate 
Calculated (M) - =1315.378; Observed=1315.343 
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2. 4. Photolytic assay 
The photolytic release of doxorubicin from the drug conjugate was analyzed using 
HPLC. The drug conjugate was dissolved in PBS buffer and was exposed to UV light at 
365 nm (9.0 mW/cm
2
). Aliquots of the reaction mixture were collected at various times 
and were analyzed on RP-HPLC. During the course of the reaction, the peaks 
corresponding to the Dox-EDANS conjugate disappeared with concomitant increase in 
the intensity of a peak with the same retention time as Dox (Figure 2.7), confirming time-
depended drug release in the presence of light.  
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Fig. 2.6: a) Release of free dox with upon irradiation over time under UV light.  A 
solution of compound 2.14 was irradiated.  Samples were removed at various time points 
(0.5, 1, 2, 4, 8, 15, 20, and 30 min) and were analyzed by RP-HPLC at λ = 480 nm.  The 
compound in the dark (t = 0) and free doxorubicin are included as standards.  b) Graph 
representing increase in intensity of integrated peak area of doxorubicin in the above time 
dependent photolysis experiment.  
Time 
of UV  
exposure 
Retention time 
a) 
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Cell line used in this project: 
For the purpose of the in vitro studies using drug conjugate, we used JH-EsoAd1 cell 
line, a Barrett's esophagus associated adenocarcinoma cell line. There are a couple of 
reasons to choose this cell line. The most important reason is that the other esophageal 
cancer cell lines such as OE33 and OE19 that are currently being used in research have 
been shown to be from other tissue types.  But this cell line has been established 
25
 to be a 
bona fide version of the esophageal adenocarcinoma cell line after extensive testing.  
Esophageal tissues have been previously shown to be accessible via endoscope in PDT, 
and PDT is a currently FDA approved treatment for the pre-malignant condition of 
Barrett’s esopagus31. Likewise, we ultimately aim to activate our photocaged drug 
molecule, in malignant organs that are accessible via endoscope, such as esophagus. 
Hence, we chose esophageal cell lines, for in vitro assays; to mimic the physiological 
conditions. 
2. 5. Flow cytometry and Confocal microscopy assays 
We then investigated whether the attachment of EDANS to Dox via the veratryl linker 
would enable drug delivery. JH-EsoAd1 cells
25
 were incubated with Dox-EDANS in the 
dark or with illumination. Cell permeability was measured with flow cytometry; upon 
illumination a significant enhancement of cellular Dox fluorescence was observed 
(Figure 2.8 A–B). This enhancement was mirrored in confocal studies with the same cell 
line (Figure 2.8 C)—only light-treated cells show significant Dox fluorescence in the 
nucleus, where it is known to accumulate.
26
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Fig.2. 7:  (A). The flow cytometry histogram displays the relative fluorescence intensity of untreated controls in the dark (blue) or 
light (red) or JH-EsoAd1 cells treated with EDANS-Dox in the dark (orange) or light (green). (B) Quantification of Dox fluorescence 
for the indicated treatment conditions. Data are representative of two independent experiments, N = 9. (C) Representative confocal 
images of JHEsoAd1 cells treated with EDANS-Dox in the dark or light. The red channel shows Dox fluorescence, the gray channel is 
a DIC image, and the overlay represents the cellular localization of Dox fluorescence. 
 
 
  
A) B) C) 
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2. 6. Cell viability assay 
With permeability enhancement established, we proceeded to investigate the extent to 
which the release of Dox with light would lead to enhanced cellular toxicity. For this 
purpose, we performed two sets of experiments. In both the experiments, we incubated 
the cells with drug conjugate at increasing time intervals at 0, 5, 10, 20 and 40 minutes.  
The first experiment was conducted in the dark whereas the second one under the 
continuous irradiation of UV light. We found that, increased illumination lead to 
decreased survival as measured by an MTT assay (Figure 2.9). Survival of cells treated 
with EDANS-Dox in the dark was equivalent to controls with no drug added. Moreover, 
treatment with light alone at the same dose was not cytotoxic (Figure 2.10). 
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Fig. 2.8:  Light-dependent cytotoxicity of Dox-EDANS. Cells were treated with 10 μM of 
Dox-EDANS with (solid diamonds) or without (open squares) light for the specified 
times. After 2 h, the cells were washed with fresh media and allowed to grow for 72 h. 
The fraction of surviving cells was evaluated using the absorbance of the formazan 
product of MTT reduction.  *Error bars denote one standard deviation from the mean.              
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Fig. 2. 9: Effect of light and EDANS on cell survival. JHEsoAd1 cells were treated with 
EDANS in the dark (blue diamonds), EDANS + light (open squares) (9 mW/cm
2
) or light 
alone (black diamonds) for the specified times. Cell survival was determined using the 
MTT assay. Each data point was taken from a minimum of six replicate experiments. 
Error bars are omitted for clarity.
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IC50 value of the drug conjugate 
Finally, we sought to compare the concentration dependence for our method vs. Dox 
alone. We first measured the IC50 of Dox alone replicating the above mentioned MTT 
assay with the JH-EsoAd1 cells and found it to be 1.0 ± 0.4 μM (Figure 2.11).  
 
 
 
 
 
 
 
Fig.2.10: Concentration-dependent toxicity of compounds on JH-EsoAd1 cells. % cell 
viability was plotted for JH-EsoAD1 cells at various concentrations of EDANS-Dox in 
the dark (open squares) or with light (black diamonds, black line), and unconjugated Dox 
in the dark (red circles, red line) or with light (blue diamonds, blue line). Experiments 
were performed in at least six replicates. Error bars are omitted for clarity. The lines are 
plots of the curve fits of the relevant data to the equation: Y = M1+ (M2-M1)/(1+X/M3). 
The constant M3 describes the IC50 value. 
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When the MTT assay was performed on cells incubated with the EDANS-Dox drug 
conjugate it was not toxic to the cells in the dark at the highest value tested (16 μM). 
However, illumination of EDANS-Dox (365 nm, 9.0 mW/cm
2
) leads to cytotoxicity with 
an IC50 of 1.6 ± 1.0 μM (Figure 2.12), comparable to that of Dox alone. Based on our 
FACS study (Figure 2.8), we deduce that this enhanced cytotoxicity is caused by efficient 
light-stimulated release of free Dox from the impermeable EDANS. 
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Fig: 2. 11: Concentration-dependent, light-stimulated cytotoxicity. Cells were treated 
with EDANS-Dox at various concentrations in the dark (open squares) or with UV light 
for 20 min (black diamonds). After 2 h, the cells were washed with fresh media and 
allowed to grow for 72 h. The fraction of surviving cells relative to no drug controls was 
evaluated using the absorbance of the formazan product of MTT reduction. Error bars 
denote one standard deviation from the mean. 
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2. 7. Discussion 
The aim of this project was to develop a new and efficient strategy for drug release based 
on photocaged permeability (PCP).  
At the outset of this project, we envisioned to use APTS (8-aminopyrene-1, 3, 6-
trisulfonate) as the hydrophilic moiety that would have contributed to the impermeability 
of the drug conjugate. But due to the sulfonic acid functional groups, the pyrene ring was 
highly deactivated; as a result of which most of the reactions did not proceed efficiently. 
Also, purification of the molecules on HPLC seemed a big challenge. As a result, we 
used EDANS, a smaller, simpler to handle, cell impermeable molecule instead. 
We chose doxorubicin as drug molecule, because it was previously described as cell 
permeable and for the photosensitive linker we chose a nitroveratryl derivative, which 
was modified to attach doxorubicin and EDANS. 
Once we synthesized the drug conjugate using the scheme mentioned in Scheme 2.4, we 
initially performed the photolysis assay to determine the efficiency of the drug conjugate 
to photo release the drug molecule. Later, we performed MTT (cell viability) assays 
using esophageal adenocarcinoma (JH-EsoAd1) cells to determine the efficiency of our 
drug conjugate to induce cell death. As expected, our drug conjugate was able to induce 
cell death, but only in the presence of light.  Also, we did several control studies to 
substantiate the fact that the cell death was actually due to drug release but not due to 
light or other entities. Further, we performed FACS (Fluorescence Assisted Cell Sorting) 
and confocal assays to show that in dark, the drug conjugate did not permeate cells. But 
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upon irradiation with UV light, the drug was released from the conjugate, permeated the 
cells and induced cell death.   
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2. 8.  Experimental section 
1. General 
All reagents were purchased from Sigma-Aldrich, Fisher Scientific or TCI America 
unless otherwise specified and were used as received. Dimethyl formamide (DMF) used 
as solvent for chemical synthesis was dried by vacuum distillation. All reactions were 
carried out in oven dried glassware and under Ar or N2 atmosphere. The reactions were 
carried out in foil-wrapped flasks, protected from light. Flash chromatography was 
performed using Flash Silica Gel (32-63μ). 1H NMR/ 13C spectra were recorded on 400 
MHz Bruker AVANCE and 300 MHz Varian instruments. HPLC purification was carried 
out using a Shimadzu Prominence system using Vydac (218TP C18 5μ) column using 
0.1% TFA in acetonitrile and water as eluents and was monitored at λmax = 480 nm. MS 
data was collected using Micromass MALDI-R/TOF (positive modes) unless mentioned. 
The UV lamp used in all studies consisted of a simple aquarium light fixture containing 
two Philips PL-S 9w/2P BLB bulbs. 
The Esophageal cancer cell line (JH-EsoAd1) was cultured at 37
o 
C and in a humidified 
atmosphere of 5% CO2 in RPMI 1640 medium supplemented with 10% fetal bovine 
serum (FBS). For 96 well plate experiments, the JH-EsoAd1 cells were seeded at 4450 
cells/well in 100 μL of media in 96 well plates; experiments were carried out one day 
after seeding. MTT assays were analyzed using a Bio-Tex μQuant plate reader at 562 nm. 
FACS was performed BD FACS Aria II using BD FACS Diva software at the VCU Flow 
Cytometry Core Facility. A minimum of 20,000 cells within the gated region were 
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analyzed. Confocal microscopy images were acquired at room temperature with a Leica 
confocal laser scanning microscope. 
  
76 
 
2.9. Chemical Synthesis 
Synthesis of 2,5-dioxopyrrolidin-1-yl 4-(4-(1-hydroxyethyl)-2-methoxy-5-
nitrophenoxy)butanoate (2.10) 
 
4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy) butanoic acid (2.9) (200 mg, 0.67 
mmoles) was dissolved in 10 ml of DMF and stirred for 5 minutes at 0
o
C. To this 
mixture, EDC. HCl (1.5 eq., 156 mg, 1.0 mmoles) was added followed by NHS (1.5 eq., 
115 mg, 1.0 mmoles). The reaction was stirred under N2 atmosphere in the dark at 0
o
C 
for approximately 1 h and then at rt for 15 h. DMF was removed in vacuo. To this 
mixture, 30 ml of EtOAc was added followed by extraction with water (3x 20 ml). The 
organic layer was dried with MgSO4, filtered and the solvent was removed under reduced 
pressure. The product obtained was single spot on TLC and was taken to the next step 
without purification. 
1
H NMR (CDCl3, 400 MHz): 
δ =7.57 (s, 1H, Ar-H), 7.39 (s, 1H, Ar-H), 5.52-5.56 (m, 1H, CH3-CH),4.17 (t, 2H, -CH2, 
J = 5.6 Hz), 3.98 (s, 3H, -OCH3), 2.85 (m, 6H), 2.29 (br.s, 1H, -CH), 2.2 (m, 3H), 1.52 
(d, 3H, -CH3, J =4.4 Hz). 
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Synthesis of 4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy)-N-(prop-2-yn-1-yl) 
butanamide (2.11): 
 
2.10(250 mg, 0.63 mmol) was dissolved in 5 ml of DMF and stirred for 5 minutes. To 
thissolution, triethylamine (2 eq., 175 μL, 1.26 mmol) was added dropwise followed by 
propargylamine (2 eq., 70 mg, 1.26 mmol). The reaction was stirred overnight at rt under 
N2 gas, in dark. Then, DMF was removed under high vacuum. To the resulting pale 
yellow oil was added EtOAc (25 ml), followed by washing with water (3 x 20 mL). The 
organic layer was dried over MgSO4 and filtered; the solvent was removed and purified 
using column chromatography (100% EtOAc) to yield pale white solid (153 mg, 72%). 
1
H NMR (CDCl3, 400 MHz):δ =7.57 (s, 1H, Ar-H), 7.31 (s, 1H, Ar-H), 5.93 (br. s, 1H, 
N-H), 5.55-5.58 (m, 1H, CH3-CH),4.12 (t, 2H, -CH2, J = 5.6 Hz), 4.06 (dd, 2H, -CH2, Jab 
= 2.4 Hz, Jac = 5.2 Hz ), 3.9 (s, 3H, -OCH3), 2.45 (t, 2H, -CH2- , J = 6.8 Hz), 2.21 (br.s, 
1H, -CH), 2.2 (m, 3H), 1.56 (d, 3H, -CH3, J =4.4 Hz). 
13
C NMR (CDCl3, 75 MHz): 
δ = 24.7, 24.9, 29.3, 32.7, 56.5, 65.7, 68.6, 71.7, 79.8, 108.9, 109.2, 137.9, 139.4, 146.8, 
154.14, 172.5. 
MS (MALDI-TOF+): C16H20N2O6Na; calculated. (M+Na)
+
 359.12, found= 359.27 
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Synthesis of 1-(5-methoxy-2-nitro-4-(4-oxo-4-(prop-2-yn-1-
ylamino)butoxy)phenyl)ethyl (4-nitrophenyl) carbonate (2.12): 
 
To a stirred solution of 2.11 (100 mg, 0.30 mmol) in dry DMF (10 ml) was added 
triethylamine (83μL, 2 eq., 0.59 mmol) followed by bis (4-nitrophenyl)carbonate (271 
mg, 3 eq., 0.89 mmol). The solution was stirred overnight in the dark at rt after which it 
was cooled and acidified with 20 mL of 1% HCl. The mixture was extracted with 30 mL 
of EtOAc and the organic layer was washed with saturated NaHCO3 (3x20 mL) solution 
and brine (1x 20 mL) and dried over MgSO4. The solution was filtered, concentrated and 
purified by flash column chromatography (1:1 to 7:3 EtOAc: hexanes) to yield pale 
yellow colored solid. (81 mg, 54 %). 
1
H NMR (CDCl3, 400 MHz):δ = 8.26 (d, 2H, Ar-H, J = 9.2 Hz), 7.61 (s, 1H, Ar-H), 
7.36(m, 2H, Ar-H), 7.12 (s, 1H, Ar-H), 6.53(q, 1H, CH3-CH, J = 6.4 Hz), 5.91 (br. s, 1H, 
N-H), 4.14(t, 2H, -CH2, J = 6.0 Hz), 4.06 (dd, 2H, -CH2, J12 = 2.4 Hz, J13 = 5.2 Hz), 4.01 
(s, 3H, -OCH3), 2.45 (t, 2H, -CH2, J = 7.2Hz), 2.21( m, 3H), 1.78 (d, 3H, -CH3, J = 8.0 
Hz). 
13
C NMR (CDCl3, 100 MHz):δ = 21.9, 24.6, 29.2, 32.5, 56.54, 68.49, 71.5, 73.7, 79.5, 
108.0, 109.1, 115.7, 121.66, 131.4, 139.9, 145.4, 147.6, 151.4, 154.1, 155.3, 171.8. 
MS (MALDI-TOF
+
): C23H23N3O10Na; calculated. (M+Na)
+
 =524.13, found =524.29 
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Synthesis of photocaged doxorubicin (2.13):  
 
 
 
 
To a stirred solution of 2.12 (80 mg, 0.16 mmol) in dry DMF (3 ml) was added 
triethylamine (45 μL, 2 eq., 0.32 mmol) followed by Dox (44 mg, 0.5 eq., 0.08 mmol). 
The solution was stirred at rt for 24 h under nitrogen, in the dark. Then, DMF was 
removed under low vacuum. To this red colored solid, 30 ml of EtOAc was added and 
washed with water (3 x 20 ml). The organic layer was dried over MgSO4, filtered and the 
solvent was removed and purified using column chromatography (silica/EtOAc and then 
1:10 MeOH: CHCl3) to yield 52% of a mixture of diastereomers. The resulting solution 
was purified on RP-HPLC using isocratic elution of 20 % organic eluent (0.1 % TFA in 
acetonitrile) for 5 minutes and then using gradient elution from 20% to 70% for 30 
minutes. The two diastereomers eluted at 35.8 and 36.9 min (See figure 2.6). The NMR 
analysis showed the presence of two products corresponding to the two diastereomers. 
1
H NMR (DMSO-d6, 400 MHz): (2x means both diastereomeric products had 
indistinguishable ppm values for those protons) 
14.05 (s,1H), 14.0 (s,1H), 13.27 (s, 2x1 H), 7.92 (m, 2x2H), 7.66 (m, 1x2H), 7.54 (s, 1H), 
7.49 (s,1H), 7.17 (s, 1H), 7.13 (s,1H), 6.05 (m, 2x1H), 5.41 (m, 2x1 H), 5.21-5.23 (m, 
2x1H), 4.95 (m, 2x1 H), 4.78-4.84 (m,2H), 4,66 (m, 2x1), 4.55 ( m, 2x2H), 3.82-4.14 (m, 
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2x11H), 3.64-3.73 (m, 4H), 3.51 (m,1x2 H), 3.05 (t, 1H, J = 2.4 Hz), 3.08 (t, 1H, J = 2.4 
Hz), 2.97 (m, 4H), 2.90 (s, 1H), 2.74 (s, 1H) 2.18-2.28 (m, 6H), 1.83-1.85 (m, 4x2H), 
1.48 (m, 3x2H), 1.10 (m, 3x2H). 
13
C NMR (DMSO, 100 MHz): 
21.92, 27.78, 46.91, 46.99, 56.15, 56.23, 56.26, 56.42, 60.18, 63.7, 66.73, 68.21, 69.74, 
72.73, 74.89, 81.21, 100.2, 108.44, 108.66, 110.41, 110.56, 118.8, 118.83, 119.47, 
119.73, 128.6, 133.54, 134.4, 135.2, 135.27, 135.98, 139.0, 139.22, 146.65, 146.69, 
153.58, 154.37, 155.68,155.92, 160.64, 171.24, 171.3, 186.22, 213.81. 
MS (MALDI-TOF): C44H47N3O18Na; calculated. (M+Na)
+
 928.28, found 928.43. 
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Synthesis of 2, 5-dioxopyrrolidin-1-yl 4-azidobenzoate (2.7): 
 
4-azidobenzoic acid (2.6) (500 mg, 3.065 mmol) was dissolved in 10 ml of DMF cooled 
to 0
o
C. To this mixture, EDC. HCl (1.2 eq., 570 mg, 3.678 mmol) was added followed by 
NHS (1.2 eq., 424 mg, 3.678 mmol). The reaction was stirred in the dark under N2 at 0
o
 C 
for approximately 1 h and then at rt for 15 h. DMF was removed in vacuo. This 
concentrated mixture was dissolved in 30 ml of EtOAc and then extracted with water (3x 
20 ml). The organic layer was dried over MgSO4, filtered, evaporated and purified using 
column chromatography (100% EtOAc) to yield 97% of pale yellow colored product. 
1
H NMR (DMSO, 400 MHz): 
δ = 8.11 (d, 2H, Ar-H, J = 8.8 Hz), 7.36 (d, 2H, Ar-H, J = 8.8 Hz), 2.90 (s, CH2, 4H). 
13
C NMR (DMSO, 100 MHz): 
δ = 25.48, 120.06, 120.46, 131.98, 146.80, 161.06, 170.32. 
MS (MALDI-TOF): C11H8N4O4Na; calculated. (M+Na)
+ 
283.04, found: 283.28 
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Synthesis of 5-((2-(4-azidobenzamido)ethyl)amino)naphthalene-1-sulfonic acid (2.8): 
 
To a stirred solution of 2.7 (50 mg, 0.192 mmol, 1.1 eq.) in dry DMF (10 ml) was added 
EtN(iPr)2 (46 μL, 1.5 eq., 0.262 mmol) followed by EDANS (47 mg, 1 eq., 0.174 mmol). 
The turbid, brown solution was stirred at rt for 10 h under nitrogen. The solvent was then 
removed under low vacuum. To the resulting brown, thick oil, 30 ml of CH2Cl2 was 
added and washed with water (3x20 ml). The organic layer was dried over Na2SO4, 
filtered and the solvent was removed in vacuo and purified using column chromatography 
(silica/15:85 MeOH: CHCl3) to yield 46 mg (64%) of a brown solid. 
1
H NMR (DMSO, 400 MHz): 
δ = 8.72 (t, 1H, -CONH-, J = 6.0 Hz), 8.07 (d, 2H, Ar -H, J = 8.4 Hz), 7.88 (m, 3H, Ar-
H), 7.27 (dd, 2H, -CH2, J12 = 7.2 Hz, J13 = 8.4 Hz), 7.21 (dd, 2H, -CH2, J12 = 8.0 Hz, J13 = 
7.6 Hz), 7.14 (m, 2H, Ar-H), 6.58 (d, 1H, Ar-H, J = 7.2Hz), 3.54 (m, 2H, -CH2), 2.99 (m, 
2H, -CH2-). 
13
C NMR (DMSO, 100 MHz): 
δ = 25.20, 45.6, 102.7, 115.6, 118.9, 122.3, 126.2, 129.1, 130.1, 130.9, 142.2, 143.71, 
143.9, 165.8, 172.7. 
MS (MALDI-TOF): C19H17N5O4SNa; calculated. (M+Na)
+
 434.09, found: 434.69 
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Synthesis of photocaged-cell impermeable dox. conjugate (2.14): 
 
Compounds 2.8 (50 mg, 0.055 mmol, 1eq.) and 2.13 (21.7 mg, 0.05 mmol, 1eq.) were 
stirred in 1:1 mixture of water and DMSO (4 mL each). 100 μL (1 mg, 0.005 mmol, 0.1 
eq.) of freshly prepared aqueous solution of sodium ascorbate (10 mg/mL) was added to 
the reaction, followed by 10 μL (0.125 mg, 0.01 eq., 0.0005 mmol) of freshly prepared 
aqueous solution of copper (II) sulfate pentahydrate (12.5 mg/ mL) was added and finally 
2.65 mg (0.1 eq., 0.005 mmol) of TBTA was added. The red colored heterogenous 
mixture was stirred vigorously until the reaction was completed (~24h) as judged by TLC 
(1: 4 CH3OH/CHCl3). The reaction mixture was concentrated in vacuo, filtered and the 
resulting solution was purified on RP-HPLC using isocratic elution of 20 % organic 
eluent (0.1 % TFA in acetonitrile) for 5 minutes and then increasing the acetonitrile 
fraction in gradient fashion from 20 % to 70% over 30 minutes at 0.5 ml/min. The 
fractions (~3 mL each) were collected into tubes containing 500 μL of ammonium 
bicarbonate (2 mg/ mL) solution to quench the TFA. The two diastereomers eluted at 
31.25 and 32.28 min.  The fractions containing the diastereomers were evaporated 
leaving a red solid (30 mg, 41%). One of the diastereomers was isolated for proton NMR 
analysis. 
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1
H NMR (DMSO, 400 MHz): 
δ =14.06 (s, 1H), 13.29 (s, 1H), 8.85 (t, 1H, J = 3.6 Hz), 8.72 (s, 1H), 8.44 (t, 1H, J = 5.2 
Hz), 8.12 (m, 1H), 8.08 (d, 2H, J = 8.8 Hz), 8.02 (d, 2H, J = 8.8 Hz), 7.91- 7.94 (m, 2H), 
7.66- 7.68 (m, 1H), 7.54 (s, 1H), 7.24 - 7.34 (m, 3H), 7.15 (s,1H), 7.0- 7.02 ( m, 1H), 
6.64 ( d, 1H, J = 7.6 Hz), 6.05 (m, 1H), 5.41( m, 2H), 5.22 ( s, 1H), 4.95 (m, 1H), 4.54 (s, 
2H), 4.40 (m, 2H), 4.06-4.11 (m, 3H), 4.00 (s, 3H), 3.92 (s, 3H), 3.61 – 3.63 (m, 3H), 
2.98 (m, 2H), 2.67 (m, 1H), 2.54 (m, 1H), 2.32(m, 2H), 2.15 (m, 2H), 1.98 ( m, 2H), 
1.84( m, 2H), 1.45 (d, 3H, J = 6.4 Hz),1.09 (m, 3H). 
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2. 10. Summary 
In summary, we have focused on applying PCP to the light-stimulated delivery of Dox 
into esophageal adenocarcinoma cells. In principle, the PCP approach could be applied to 
any small, cell permeable molecule that has a free amine, hydroxyl, or carboxylic acid 
group for attachment of the veratryl-EDANS molecule. 
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CHAPTER: 3. 
DUAL SPECIFICITY: 
A NEW APPROACH TO INCREASE THE SPECIFICITY OF DRUG 
TARGETING. 
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Abstract:  
Light is used as a source to improve the specificity of certain ligand-drug conjugates. 
Here, we describe the synthesis of two drug conjugates appended to two different tumor 
receptor binding ligands. These molecules are similar to the previously existing ligand-
drug conjugates, but differ in the fact that once internalized into the tumor cells; they 
remain inactive, unless irradiated with light.  
3.1. Introduction 
Selectivity of pharmacological action is of central importance in drug therapy. Hence, the 
development of targeted drug action is particularly important in minimizing the adverse 
side effects associated with current cancer chemotherapeutics. Several approaches that 
specifically target tumors have been reported
 1
. These approaches act either by interfering 
with the oncogenic pathways
2
 or by targeting an over-expressed receptor
3
. The latter 
approach employs a ligand that binds specifically to an over-expressed receptor and is 
appended to a cytotoxic drug. This approach has an advantage over others because of 
improved specificity of the drug action; hence reduced side-effects.  
Folic acid (vitamin B9)
4
 is required in metabolic reactions in cells and is essential for 
synthesis of nucleotide bases; this ligand has a high affinity towards folate receptors 
(FRs). FRs are expressed normally in healthy tissues, but are expressed at elevated levels 
in tumor tissues. Hence for this reason, FR targeting is actively being pursued for 
imaging and therapeutic purposes by conjugating FA with the imaging or drug molecules.  
PSMA
 
(Prostate Specific Membrane Antigen) is a plasma membrane glycoprotein
5
 that is 
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overexpressed in prostate cancer. Several ligands that display high binding affinity 
toward PSMA are currently being used toward targeting the prostate cancer
6
. 
But ligand targeted therapies have some inherent problems such as endosomal 
entrapment and non-selective drug release. Endosomal entrapment refers to retention of a 
drug conjugate inside the endosomes
7
. As a result, rapid release of the drug from 
endosomes is not always efficient
8
. The other problem that affects ligand targeted therapy 
is that the mode of activation of these drug conjugates is dependent only on few 
functional groups that mediate facile release of the drug
9
; which could also happen even 
before the conjugate internalizes, leading to non-specific drug action. In wake of these 
limitations, a modified ligand-drug conjugate is essential that can overcome most of the 
above mentioned drawbacks. 
Light is a non-invasive source of drug activation and has been found to be efficient in 
activation of drug molecules intracellularly
10, 11, 21
. PDT is tumor treatment modality that 
depends on light and photosensitizer to produce singlet oxygen, a cytotoxic agent. But 
application of PDT in tumor treatment is limited by the fact that there is not always 
enough oxygen present in the tumor environment
12
. To address these limitations, we 
recently reported a novel and efficient drug release system using photocaged drug 
molecule
13
. Though this system works efficiently, a better system is needed to improve 
the specificity of drug action. 
In this chapter, we report the concept of Dual Specificity.  In this approach, we envision 
that by coupling a tumor-receptor targeting ligand (folic acid or PSMA binding ligands) 
with photocaged drug molecule; the ligand-drug conjugate could selectively target the 
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tumor receptor, internalize and concentrate in tumor cells. And when irradiated with 
light, the drug molecule is decaged; eventually causing cell death. 
The advantages of this approach over the traditional targeted therapy would be that even 
after internalization, the drug conjugate would remain latent; even if it leaks out of 
endosomes. But once activated using light directed only to the tumor site, the drug is 
cleaved from the conjugate and induces cell death.  
 
Fig. 3.1: Strategy for dually specific drug delivery system 
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3.2. Building blocks to design targeted photocaged drug conjugate   
Spacer 
Receptor binding 
ligand  
Drug 
Receptor binding 
ligand 
Desirable characteristic of 
ligands 
 
 Tight binding with 
tumor specific 
receptor 
 Should have 
functional group 
that doesn’t 
influence binding 
Drug 
Nitroveratryl linker 
1) Light sensitive 
2) Should have 
functional 
groups to hold 
drug and 
impermeable 
moiety 
 
Doxorubicin 
 Cell 
permeable 
 Functional 
group for 
attachment 
 
Photocleavable Linker Spacer 
Desirable characteristic 
of spacer 
 Long enough to 
give space for 
ligand to bind 
to receptor 
 Water soluble 
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3.3 Design of targeted photocaged drug conjugate 
In this section, we will be following the same steps that were previously described in 
chapter 2, to design photocaged drug conjugated to tumor receptor binding ligands. In 
that same chapter, we have rationalized the usage of drug and photocleavable linker 
components. Hence in this section, we will focus only on the design of ligand and spacer. 
Ligands: 
Previously in our design of the drug conjugate, we attached a hydrophilic moiety to a 
photocaged drug conjugate via ‘click’ chemistry. Without any major changes to the 
existing design; we envisioned to replace the hydrophilic moiety with the tumor receptor-
specific ligands.  
At the onset of this project, we sought ligands that bound tightly to the tumor specific-
receptor. Immediately, we found several vitamins, growth factors and some inhibitors 
that exhibited high affinity towards their respective receptor and also were becoming 
increasingly popular for the purposes of imaging and targeting drug molecules to the 
tumor tissues. Hence, we concluded our search after finding Folic acid and 2-[3-(1, 3-
dicarboxypropyl)ureido]pentanedioic acid (DUPA) ligands. The folate receptor and 
PSMA mechanism of drug internalization has already been described in chapter 1. Hence, 
we will be focusing only on the design of the drug conjugate. 
Folic Acid: 
Folate receptors (FRs)
4
 are overexpressed in many different cancers such as ovarian, 
lung, kidney, breast and brain. Folic acid-FA (vitamin B9) is a small molecule that has 
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very high affinity towards FRs and binds tightly with them. For these reasons, FA 
conjugated drug and imaging molecules are being used extensively in current research 
and clinical studies.  
Folic acid has two components, pteroic and glutamic acids (Fig. 3.2 a) that are conjugated 
via a peptide bond. The α-COOH on glutamic acid is believed to play a key role in the 
internalization of the folic acid-drug conjugate and γ-COOH was reported to be non-
essential for FR binding. Hence, the γ-COOH was modified to attach a variety of 
molecules. But there seems to be some controversy surrounding the previous statement
20
. 
Recently, Baker, Jr. and group reported
22
 that conjugation on either α-COOH or γ-COOH 
did not virtually affect the binding capability. But in any respect, both carboxylates play 
some role in binding affinity toward FRs.  
PSMA Binding Ligands 
PSMA is the most commonly studied receptor associated with prostate cancer. These 
receptors are overexpressed in prostate cancer. Recently, several groups initiated the 
approach of using the low molecular weight ligands that selectively bind to PSMA to 
study the progression of diseases. These ligands have been found to have sub-nanomolar 
binding affinities towards PSMA
6
. Indeed, many of them have been radio-labeled, for 
imaging studies and in some cases these ligands were conjugated to the drug molecules 
for therapeutic purposes
19
.   
The most commonly used PSMA binding ligands are urea derivatives (Fig. 3.2 b). Out of 
many ligands analyzed; using in silico docking studies
5
, the DUPA ligand was found to 
have multiple interactions with amino acids in the PSMA and hence displayed very high 
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affinity. Interestingly, DUPA has three carboxylic units (α, γ, γ’), of which γ’ is found to 
be non-essential for the binding purposes, similar to γ-COOH of folic acid. Hence the γ’-
COOH could be used to conjugate any imaging or therapeutic agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2: a) Folic acid and b) PSMA binding urea based ligand 
 
 
Site of drug 
attachment 
Site of drug 
attachment 
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Spacer:  
Spacers are one of the important components that are incorporated into designs of any 
receptor targeted drug conjugate to promote effective ligand-conjugate binding to the 
receptor and also increase its solubility in physiological buffers. In general, spacers are 
equipped with appropriate functional groups that can react with both the ligand and the 
drug conjugates, so as to append one to another. The length of the spacer is critical for the 
purpose of imaging and drug delivery, because if the length is too short, it may possibly 
reduce the binding affinity and efficiency. But if the spacer is too long, it can potentially 
loop back and then hinder the ligand-receptor interaction. 
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Retrosynthetic analysis  
After completing the synthesis of the ligand-spacer azide conjugates and photocaged dox 
conjugate (Scheme 2.4), we planned to assemble the desired photocaged drug-ligand 
conjugates using click chemistry as shown below. 
. 
 
Fig. 3.3: Strategy for synthesis of photocaged drug-ligand conjugate 
  
Click 
chemistry 
Peptide coupling 
reaction 
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3.4 Design of ligand-spacer azide derivative for ‘click’ chemistry: 
Since we had already established the protocol for synthesis of alkyne derivatized 
photocaged doxorubicin (2.13), we envisioned to synthesize an azide derivatized ligand 
spacer, such that we can couple both the entities via click chemistry.  
Synthesis of Azide Derivatized Spacer 
At this point, we first acquired an ethylene oxide spacer containing free amines (-NH2) at 
each of its ends (3.1). Primarily, our main goals were to couple an azide moiety to one of 
these amine units and use the other amine to couple to the ligand, via standard peptide 
coupling chemistry. 
In our attempt to synthesize the azide derivatized spacer (Scheme 3.1), we attached 4-
Azidobenzoic succinimidyl ester (2.7) to 1,8-Diamino-3,6-dioxaoctane (3.1) in the 
presence of triethylamine and DMF. The azido-spacer product (3.2) was furnished in 
good yield. 
Scheme: 3.1 Synthesis of ligand-spacer azide derivative. 
Reagents and conditions: a) Triethylamine (Et3N), DMF at 0
o
C to rt over 2 h 
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Synthesis of Ligand-Spacer Azide Derivative 
The synthesis of ligand-spacer conjugate is same for both ligands. But we will be 
discussing the synthesis of each ligand-drug conjugate individually. 
i) Folic Acid-Spacer Conjugate 
The synthesis of Folic acid-spacer conjugate (Scheme 3.2) started with solubilizing folic 
acid (3.3) in DMF to form thick a viscous solution. To this solution, we added DCC and 
N-hydroxysuccinimide to form the folate succinimidyl ester (3.4) which, after removal of 
excess unreacted starting materials using acetone/ether precipitation, was taken to the 
next step without further purification. This solid was stirred with azido derivatized spacer 
(3.2), in DMF in the presence of triethylamine to give compound (3.5) in moderate yield. 
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Scheme: 3.2: Synthesis of folic acid-spacer azide derivative. 
Reagents and conditions: a) DCC, DMF b) 3.2, Et3N, 
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i) PSMA Binding Ligand-Spacer Conjugate 
For the synthesis of the PSMA ligand, we first acquired L-glutamate di-tert-butyl ester 
hydrochloride (3.6) and L-Glu(OBn)-OtBu (3.7), and coupled them via their amines 
using triphosgene in basic conditions to form urea derivative 3.8. Later the benzyl group 
on the core ligand was deprotected using Pd/C to give carboxylic acid 3.9. After 
purification, this solid was treated with N-hydroxysuccinimide in presence of EDAC in 
DMF to yield 3.10, which was taken to the next step without purification. To the solution 
of 3.10 in DMF, we added the spacer (3.4) in the presence of triethylamine to form 3.11. 
The Boc protecting groups were cleaved with 20% TFA in DCM to form an azide-
derivatized DUPA (3.12), in moderate yield. 
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Scheme: 3.3: Synthesis of DUPA-spacer azide derivative. Reagents and conditions: a) 
Triphosgene, Et3N, CH2Cl2b) H2, Pd/C, MeOH c) NHS, EDAC, DMF d) Et3N, DMF e) 
20% TFA in CH2Cl2 
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Scheme 3. 4: Synthetic scheme for synthesis of photocaged drug-ligand conjugate 
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3.5. Synthesis of photocaged drug-ligand conjugates 
For the synthesis of folate and DUPA drug conjugates, we used both azide derivatized 
ligands 3.5 and 3.12; coupled them with Dox alkyne 2.13 in two different reaction 
vessels using click chemistry. The contents were solubilized in 1:1 DMSO and water in 
presence of CuSO4, sodium ascorbate and TBTA which eventually yielded 3.13 as folate 
drug conjugate in a low yielding reaction and 3.14 as DUPA drug conjugate. HRMS of 
the red colored solid 3.13 is shown in Fig. 3.4 
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Fig. 3.4: HRMS (ESI) (C76H83N15NaO26) of 3.13, Calculated Mass 1644.55 
Obtained mass (HRMS): 1644.474 
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Fig. 3.5: RP- HPLC analysis of 3.13, using absorbance at 480 nm. The two diastereomers 
have retention times of 19.5 and 20.8 min. 
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3.6. Representative photolytic assay to describe drug release from photocaged drug -
ligand conjugate 
The photolytic release of doxorubicin from the photocaged drug-folic acid conjugate 
(3.13) was analyzed using HPLC. The drug conjugate was dissolved in PBS buffer and 
was exposed to UV light at 365 nm (9.0 mW/cm
2
). Aliquots of the reaction mixture were 
collected at various times and were analyzed on RP-HPLC. During the course of the 
reaction, the peaks corresponding to the 3.13 disappeared with concomitant increase in 
the intensity of a peak with the same retention time as Dox (Fig.3.6), confirming time-
depended drug release in the presence of light.  
When the percentage release of doxorubicin relative to the drug conjugate was plotted on 
the graph, it was found that the majority of doxorubicin was released within first 4 
minutes of the irradiating the UV light and at the later time points, the drug release 
plateaued. This data suggests that the doxorubicin release from the drug conjugate is 
rapid.  
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Fig. 3.6: Time dependent release of doxorubicin from the folic acid-photocaged drug 
conjugate under UV light.   
A solution of compound 3.13 was irradiated with UV light and samples were removed at 
various time points (0.5, 1, 2, 4 and 8 min) and were analyzed by RP-HPLC at λ = 480 nm.   
The compound in the dark (t = 0) and free doxorubicin are included as standards. 
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Fig. 3.7: Graph representing increase in the % doxorubicin released from drug conjugate 
over period of 8 minutes. 
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3.7. Discussion and Conclusion 
The aim of this project is to develop drug conjugates that have improved target specificity 
due to the incorporation of light sensitive linker connecting tumor specific ligands to drug 
molecule and test it on the tumor cells. 
Here, we synthesized two different drug conjugates that are expected to bind only to 
tumor cells. Specifically, we incorporated tumor receptor binding ligand (Folic acid and 
DUPA) in our drug conjugate design and attached it to the photocaged doxorubicin 
conjugate via click chemistry.  We later tested the efficiency of one of the drug 
conjugates (Folic acid-drug conjugate) to release the drug molecule under UV irradiation. 
We found that drug release from the conjugate is extremely fast and quantitative. 
Future Directions: 
In this project, our aim was to improve the selectivity of drug action by incorporating a 
tumor specific receptor binding ligand in our photocaged drug conjugate design. And for 
this purpose, we acquired two cell lines for each ligand-drug conjugate; one of the two 
overexpresses the receptor protein and the other does not express the receptor at all. 
Below, we throw some light on the cell lines that will be employed in future studies. 
Cell lines 
Folic acid: 
We acquired two different cell lines, RT16 and R2 to demonstrate efficiency of the 
photocaged drug conjugate. These two cell lines are isogenic cell line models which were 
specifically developed to study certain antifolates
14
. 
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RT16 is a CHO cell line that overexpresses FR-α, which has been developed by 
transfections of cDNA of the folate receptor protein. Whereas R2 cell lines are used as 
FR-null, which means the gene that expresses FRs in CHO cells has been knocked out. 
PSMA 
LnCaP cells are derived from metastatic lesion of prostatic adenocarcinoma of a human 
patient
15
 that overexpress PSMA. These cell lines grow slower than other prostatic cancer 
cell lines, a fact attributed to the overexpression of PSMA on their plasma membrane
16
.  
DU145 cells
17
 are human prostate cancer cell lines which have been traditionally used for 
prostate cancer research. These cell lines do not express PSMA at all and hence have 
been used as negative control for PSMA dependent studies.  
Cell Studies: 
To reiterate the selectivity of the ligand towards their respective receptors, we will 
initially perform confocal microscopy
18
 based assays using the above cell lines. Later, we 
will be quantifying the amount of fluorescence in these cells using flow cytometry
24
. At 
the end, we will be analyzing the viability of cells in presence of respective drug 
conjugate using MTT assay
25
.  
Conclusion: 
Once the future goals of the described approach is completed, we will have two light 
sensitive targeted drug delivery systems that can serve as better drug delivery vehicles for 
tumor targeting and reducing side effects caused due to non-specific delivery. 
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3.8. Experimental section 
General 
All reagents were purchased from Sigma-Aldrich, Fisher Scientific or TCI America 
unless otherwise specified and were used as received. All reactions were carried out in 
oven dried glassware and under Ar, H2 or N2 atmosphere. The reactions were carried out 
in foil-wrapped flasks, protected from light. Flash chromatography was performed using 
Flash Silica Gel (32-63μ). 1H NMR/ 13C spectra were recorded on 400 MHz Bruker 
AVANCE and 300 MHz Varian instruments. HPLC purification was carried out using a 
Shimadzu Prominence system using Vydac (218TP C18 5μ) column using 0.1% TFA in 
acetonitrile and water as eluents and was monitored at λmax = 480 nm. M/S data was 
collected using Micromass MALDI-R/TOF (positive modes) unless mentioned. The UV 
lamp used in all studies consisted of a simple aquarium light fixture containing two 
Philips PL-S 9w/2P BLB bulbs. 
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3.9. Chemical synthesis of photocaged drug-folate conjugate 
Synthesis of Photocaged doxorubicin has already been described in the experimental 
section of Chapter 2. 
Synthesis of N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-4-azidobenzamide (3. 2) 
 
 
 
A solution of the NHS activated 4-azido benzoic acid (1) ( 260 mg, 1.0  mmol, 1eq.) in 7 
mL of DMF was added dropwise over 30 mins into an ice-cooled solution of 2, 2’-
ethylenedioxy bis-(ethylamine) (1a) (600 mg, 4.0 mmol, 4 eq.) in  3  mL of DMF. The 
reaction mixture was stirred for an hour at 0
o
C and then for about 5 h at room 
temperature in dark condition.  The solvent was removed in vacuo and the resulting 
mixture was purified using flash column (4:2:0.1 DCM: EtOH: NH4OH) to give 79% of 
the oily product (231 mg).  
1
H NMR (CDCl3, 400 MHz):δ = 7.83 (m, 2H, Ar-H), 7.11 (br. s, 1H, CONH), 7.05 (m, 
2H, Ar-H), 3.65 (m, 8H, -CH2-), 3.51 (t, 2H, J= 5Hz, -CH2-), 2.85 (t, 2H, J= 5Hz, -CH2-
), 1.90 (br. s, 2H, -NH2). 
13
C NMR (CDCl3, 100 MHz): δ = 166.58, 143.12, 131.15, 128.95, 118.85, 73.18, 70.27, 
70.11, 69.84, 41.62, 39.82.  
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Synthesis of folate-linker (3.5): 
 
 
 
Folic acid (1 g, 2.26 mmol) was dissolved in 20 mL of dry dimethylformamide (DMF) to 
which 1.5 eq. of DCC (700 mg, 3.4 mmol) and 1.5 eq. of NHS (0.39 mg, 3.4 mmol) were 
added. This formed a very viscous orange colored reaction mixture, which was stirred for 
16 h at room temperature in the dark. The byproduct, dicyclohexylurea, was filtered off, 
and 100 mL of 30% acetone in diethyl ether was added with stirring, which formed 
orange precipitate. This precipitate was washed again with acetone: ether mixture for 
several times. This mixture was then mixed with ether in a falcon tube; which was 
vortexed vigorously and centrifuged at 2000 rpm. The ether supernatant was discarded 
and the light orange-colored Folate-NHS ester was dried and taken to next step. 
Folate-NHS ester (156 mg, 0.29 mmol) was dissolved in 20 ml of DMF while stirring. To 
this solution, 2 eq. of 3.2 was added (170 mg, 0.58 mmol) along with 2 eq. of TEA (50 
µL, 0.58 mmol). The mixture was stirred at room temperature in the dark for 16 h. After 
DMF and TEA was evaporated, the resulting compound was washed with 30% acetone in 
ether as mentioned above. The resulting solution was lyophilized to yield orange solid 
that needed no further purification.  
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1
H NMR (CDCl3, 400 MHz): 
8.64 (1H, m, Fol-H) , 8.55 (1H, m, 2x CONH), 7.83-7.92 (3H, m, spacer Ar-H and 
CONH ), 7.56-7.63 (2H, m,Fol Ar-H  ), 7.18-7.22 (3H, m, spacer Ar-H and -CONH),  
6.89(1H, m, Fol-NH), 6.65 (2H, m, Fol Ar-H), 4.48 (2H, m, Ar-CH2), 4.24 (1H, m,-CH-) 
3.40-3.57 (10 H, m, -CH2 -CH2 -O-), 3.17 (2H, m, -CH2 -CH2 -O-),), 2.16-2.25 (2H, m, 
Glu-H), 1.91-1.93 (2H, m, Glu-H) 
 
13
C NMR (CDCl3, 100 MHz): 
174.29, 174.09, 171.98, 166.12, 166.10, 165.48, 165.44, 162.37, 161.20, 154.02, 150.69,  
148.50, 148.45, 142.25, 142.19, 130.92, 130.88, 129.06, 128.79, 127.86, 121.54, 121.46,  
118.84, 118.81, 118.77, 112.56, 111.24, 111.16, 69.63, 69.49, 69.40, 68.81, 66.65, 35.77 
30.77 
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Syntheses of fol dox conjugate (3.13):
 
Compounds 3.5 (32 mg, 0.044 mmol, 2 eq.) and 2.13 (21 mg, 0.022 mmol, 1eq.) were 
stirred in 1:1 mixture of water and DMSO (2 mL each). 100 μL (1 mg, 0.005 mmol, 0.1 
eq.) of freshly prepared aqueous solution of sodium ascorbate (10 mg/mL) was added to 
the reaction, followed by 10 μL (0.125 mg, 0.01 eq., 0.0005 mmol) of freshly prepared 
aqueous solution of copper (II) sulfate pentahydrate (12.5 mg/ mL) was added and finally 
2.65 mg (0.1 eq., 0.005 mmol) of TBTA was added. The red colored heterogenous 
mixture was stirred vigorously until the reaction was completed (~24h) as judged by TLC 
(1: 4 CH3OH/CHCl3). The reaction mixture was concentrated in vacuo, filtered and the 
resulting solution was purified on RP-HPLC using isocratic elution of 20 % organic 
eluent (0.1 % TFA in acetonitrile) for 5 minutes and then increasing the acetonitrile 
fraction in gradient fashion from 20 % to 100% over 30 minutes at 10 ml/min. The 
fractions (~10 mL each) were collected into tubes containing 1000 μL of ammonium 
bicarbonate (6 mg/ mL) solution to quench the TFA. The two diastereomers eluted at 
19.5 and 20.8 min.   
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3.10. Chemical Synthesis of DUPA-Photocaged drug conjugate: 
Synthesis of (R)-5-benzyl 1-tert-butyl 2-(3-((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-
yl)ureido)pentanedioate (3.8). 
 
Synthesis of 3.8 was performed according to a reported procedure
5
. To a solution of L-
glutamate di-tert-butyl ester hydrochloride (333 mg, 1.12 mmol. 3 eq.) and triphosgene 
(111 mg, 0.373 mmol. 1 eq.) in 10 mL DCM at −78 °C, triethylamine (322 µL, 2.31 
mmol., 7 eq.)  was added. After stirring for 2 h at −78 °C under argon, a solution of L-
Glu(OBn)-O
t
Bu (330 mg, 1.19 mmol. 3.2 eq.) and TEA (210 µL, 1.5 mmol. 4 eq.)  in 5 
mL DCM was added. The reaction mixture was allowed to come to room temperature (rt) 
over a period of 1 h and stirred at rt overnight. The reaction was quenched with 1 M HCl, 
and the organic layer was washed with brine and dried over Na2SO4. The crude product 
was purified using flash chromatography (hexane:EtOAc = 1:1) to yield a colorless oil. 
1
H NMR (CDCl3, 400 MHz): δ= 7.314(5H, m, Ar-H), 5.007-5.143 (4H, m, urea-H and 
Ar-CH2-), 4.302-4.404 (2H, m, -CH-), 2.263-2.488 (4H, m, -CH2-), 2.023-2.207 (2H, m, -
CH2-), 1.806-1.974(2H, m, -CH2-), 1.428-1.461 (27H, m, Boc-) 
13
C NMR (CDCl3, 100 MHz): 
173.1, 172.55, 172.38, 172.21, 157.33, 136.07, 128.64, 128.34, 128.29, 82.02, 81.95, 
80.5, 66.48, 53.13, 53.07, 31.74, 30.54, 28.67, 28.59, 28.22, 28.13. 
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 Synthesis of (R)-5-(tert-butoxy)-4-(3-((R)-1, 5-di-tert-butoxy-1, 5-dioxopentan-2-
yl)ureido)-5-oxopentanoic acid (3.9). 
 
To a solution of 9 (250 mg, 432 mmol) in MeOH, 5% Pd/C was added. The reaction 
mixture was hydrogenated at 1 atm for 24 h at rt. Pd/C was filtered through a Celite pad 
and washed with DCM. The crude product was purified using flash chromatography 
(hexane:EtOAc = 40:60) to yield colorless oil (175 mg, 83%). 
1
H NMR (CDCl3, 400 MHz): 
5.40 (2H, m, Urea-H), 4.32-4.40 (2H, m, α-H), 2.29-2.41 (4H, m, Glu-H), 1.87-2.11 (4H, 
m, Glu-H), 1.43-1.46 (27H, m, Boc) 
13
C NMR (CDCl3, 100 MHz): 
152.61, 152.20, 150.44, 150.37, 143.29, 114.30, 91.60, 87.31, 85.06, 83.68, 81.38, 63.50, 
27.80, 27.25, 25.88, 25.37, 18.34 
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Syntheses of Boc-protected DUPA-spacer conjugate (3.11): 
 
 
 
 
 
 
150 mg (0.31 mmol, 1 eq.) of 3.9 was solublized in 10 ml DMF and stirred. To this 
solution, 71 mg (0.614 mmol, 2 eq.) of NHS and 95 mg (0.614, 2eq.) of EDAC were 
added and stirred overnight, in an aluminium foil covered flask. Later, the DMF solvent 
was evaporated in vacuo and the crude reaction mixture was extracted with DCM and 
water followed by brine solution. The impure white colored solid (3.10) was taken to next 
step without further purification.  
In the next step, the crude DUPA-NHS solid (~100 mg) was stirred in 10 mL DMF. To 
this solid about 150 mg (0.512 mmol, ~3 eq.) of 3.2 was added to the mixture along with 
triethylamine (71 μL, 0.512 mmol, 3 eq.) and stirred for about 16 h. The DMF was 
evaporated and the crude mixture was extracted with DCM and 1 M HCl solution.. Later, 
DCM was evaporated and the resulting brown colored oil was purified using a flash 
column (10% MeOH in DCM) to yield 169 mg (63% with spacer contamination) of 
brown colored oil.  
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1
H NMR (CDCl3, 400 MHz): 
7.88 (2H, d, J=8.4 Hz), 7.83 (2H, d, J=8.4 Hz), 7.38 (1H, m), 7.04-7.08(4H, m), 6.95 (1H, 
m), 6.85 (1H, m), 5.80 (1H, d, J=8.4 Hz), 4.49 (1H, m), 4.13-4.18 (m, 2H), 3.41-3.6 (m, 
24 H), 3.16-3.2 (m,1H), 2.25-2.29 (m, 5H), 1.41-1.46 (m, 37H) 
Note: NMR indicates presence of extra linker despite extra careful purification.  
13
C NMR (DMSO, 75 MHz): 
167.09, 166.95, 165.87, 161.46, 161.34, 152.50, 138.06, 137.89, 125.77, 125.73, 123.79, 
123.61, 113.69, 113.62, 76.74, 76.72, 75.38, 64.97, 64.75, 64.59, 64.07, 48.15, 47.74, 
34.55, 34.03, 33.56, 27.62, 26.55, 24.40, 23.83, 22.82, 22.75, 22.71, 22.41 
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Removal of Boc protection on DUPA-spacer conjugate (3.12): 
 
. 
To a solution of 3.11 (169 mg, 0.22 mmol) in 8 mL of DCM, 2 mL of TFA was added  
and stirred for about 8 h at rt. Later, DCM and TFA were evaporated in vacuo. To the 
pale colored oily solid, about 25 mL of cold ether was added.  The suspension was 
vortexed for about 5 minutes and then centrifuged in a 50 mL of falcon tube. This 
procedure was repeated a second time yielding a brown colored oil 45% yield (50 mg). 
1
H NMR (CDCl3, 400 MHz): 
12.46 ( 3H, br.s, 3xCOOH), 8.50 ( 1H, m, CONH), 7.90 (2H, m, Ar-H), 7.19 (2H, m, Ar-
H), 6.34 (1H, t, CONH, J= 8.8 Hz), 4.07-4.11 (2H, m, Urea-NH), 3.92 (2H, m, -CH-), 
3.53 (8H, m, -CH2 -CH2 -O-), 3.41 (4H,m, -CH2 -CH2 -O-), 2.14-2.26 (4H, m, Glu-H), 
1.73-1.92 (4H, m, Glu-H) 
13
C NMR (DMSO, 75 MHz): 
175.31, 175.27, 174.69, 158.02, 152.24, 129.35, 128.66, 113.18, 70.19, 69.72, 53.01, 
52.68, 52.62, 52.03, 46.26, 32.29, 30.81, 29.13  
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Syntheses of DUPA dox conjugate (3.14): 
 
Compounds 2.13 (20 mg, 0.022 mmol, 1eq.) and 3.12 (27 mg, 0.044 mmol, 2eq.) were 
stirred in 1:1 mixture of water and DMSO (2 mL each). 40 μL (0.4 mg, 0.002 mmol, 0.1 
eq.) of a freshly prepared aqueous solution of sodium ascorbate (10 mg/mL) was added to 
the reaction, followed by 12.5 μL (0.125 mg, 0.03 eq., 0.0006 mmol) of freshly prepared 
aqueous solution of copper (II) sulfate pentahydrate (12.5 mg/ mL), and finally 1.1 mg 
(0.1 eq., 0.002 mmol) of TBTA (Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine) was 
added. The red colored heterogenous mixture was stirred vigorously until the reaction 
was completed (~24h) as judged by TLC (1: 4 CH3OH/CHCl3). The reaction mixture was 
concentrated in vacuo, filtered and the resulting solution was purified on RP-HPLC using 
isocratic elution of 20 % organic eluent (0.1 % TFA in acetonitrile) for 5 minutes and 
then increasing the acetonitrile fraction in gradient fashion from 20 % to 100% over 30 
minutes at 10 ml/min. The fractions (~10 mL each) were collected into tubes containing 
1000 μL of ammonium bicarbonate (6 mg/ mL) solution to quench the TFA.  
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CHAPTER: 4. 
UPCONVERSION NANOPARTICLES MEDIATED DRUG DELIVERY 
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Abstract:  
Controlled release of the drug molecule from the photocaged drug conjugate suffers from 
an intrinsic weakness of dependence on UV light. To address this limitation, we report 
the synthesis of a photocaged drug conjugate that will be attached to Upconversion 
Nanoparticles (UCNPs).  
4.1. Introduction: 
Current chemotherapy suffers from off-target action of the drug molecules and as a result 
there are unwanted side-effects. To address this limitation, we reported two different 
mechanisms of drug delivery, in Chapters 2 and 3, which are dependent on light. 
Specifically, we demonstrated controlled release of the drug using a photocaged drug 
conjugate as our first model and later described the design and synthesis of ligand-
photocaged drug conjugate for site specific drug delivery.  However, these drug delivery 
systems suffer from a common intrinsic weakness of being activated only in the presence 
of UV light.  
The penetrability of UV radiation
1, 2
 into human skin is limited due to the fact that there is 
absorption and scattering of the incident light due to cells and its organelles, blood 
vessels etc. Also, UV light is reported to be cytotoxic
3
 as a result of high energy radiation 
that can cause DNA damage
4
.  As a result, photocaged drug conjugates that are UV 
dependent for the purpose of drug delivery; face challenges when applied in vivo.  Hence, 
it is crucial to address the issue of drug release inside deep tissues, where external UV 
light cannot penetrate.  
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Upconversion Nanoparticles (UCNPs) refer to the lanthanide doped nanocrystals that 
emit high energy rays when irradiated with NIR (Near Infrared) radiation (Fig. 4.1). 
Specifically, the UCNPs are made of host lattices
5
 such as NaYF4, Y2O3 etc. embedded 
with trivalent dopants such as Yb
3+
, Er
3+
 and Tm
3+
. Because of its upconversion 
capability, these nanoparticles are currently being applied for the purposes of therapy
6
 
and imaging
7
. 
UCNPs are usually prepared in presence of certain capping ligands that control particle 
growth and stabilize the particles against aggregation. These ligands contain functional 
groups that are helpful for later functionalization of UCNPs with imaging or drug 
molecules
8, 9
. Recently, Capobianco and group
10
 reported the usage of LiYF4:Tm
3+
, 
Yb
3+
UCNPs, to demonstrate their ability to photoswitch. Specifically, these UCNPs were 
attached to a bis-spiropyran moiety via dicarboxylate functional groups. When irradiated 
with NIR, the non-fluorescent bis-spiropyrans underwent photoswitching to form 
fluorescent merocyanine units.   
We envision connecting photocaged doxorubicin onto the surface of the above mentioned 
UCNPs via dicarboxylate units. Particularly, we will be designing and synthesizing the 
photocaged doxorubicin-carboxylate ligand and using it toward functionalizing the 
UCNPs. Later, we will be able to use the UCNP-drug conjugate for the purpose of drug 
delivery under the irradiation of NIR.  
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Fig. 4.1: Schematic description of UCNP mediated upconversion of NIR to UV 
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4. 2. Building blocks to design photocaged drug-carboxylate ligand conjugate   
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Fig. 4.2 Graphical description of UCNP mediated drug release   
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Since we already described the design of photocaged drug molecule (chapter 2), we will 
just focus on the design of the dicarboxylate ligand in this section. 
Dicarboxylate Ligand: 
At the outset of this project, we envisioned to synthesize an azide derivatized 
dicarboxylate unit, since we already have synthesized the photocaged doxorubicin (2.13), 
which has an alkyne functionality; which will be later coupled via click chemistry.  
We decided to use the same azide derivative of the benzoic succinimidyl ester (2.7) that 
was previously used to derivatize various ligands (chapter 2 and 3).  
Finally, we sought dicarboxylic units with an amine functionality that could be used in 
coupling reaction with 2.7. We decided to use Boc-protected glutamic acid (3.6) for this 
purpose (Fig. 4.3).  
Synthesis of azide derivatized dicarboxylate ligand. 
We attached 4-Azidobenzoic succinimidyl ester (2.7) to L-glutamate di-tert-butyl ester 
hydrochloride (3.6) in the presence triethylamine and DMF. The azido derivatized amino 
acid product (4.2) was furnished in good yield. Later, the Boc-protecting group was 
removed in presence of 20% TFA in DCM to yield azide derivatized dicarboxylate 4.3 
(Scheme 4.1).  
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Retrosynthetic analysis  
After completing the synthesis of the azide derivatized dicarboxylate ligand (scheme 
4.1), and photocaged dox conjugate (scheme 2.4), we planned to assemble the desired 
photocaged drug-ligand conjugates using click chemistry as shown below. 
 
  
Click 
chemistry 
Peptide coupling 
reaction 
Fig. 4.3: Strategy for synthesis of photocaged drug-ligand conjugate 
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Scheme 4.1: Schematic synthesis of photocaged drug-dicarboxylate ligand conjugate: 
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4. 3 Syntheses of photocaged drug- carboxylate ligand conjugate 
For the syntheses of the drug conjugate, we used both azide derivatized ligand 4.3 and 
coupled it with Dox alkyne 2.13 using click chemistry. The contents were solubilized in 
1:1 DMSO and water in presence of CuSO4, sodium ascorbate and TBTA which 
eventually yielded photocaged drug-dicarboxylic conjugate, 4.4.  FT-MS of the red 
colored solid 3.13 is shown in Fig. 3.4. 
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4.4 Discussion  
The aim of this project is to synthesize a drug conjugate that could be grafted onto a 
previously designed UCNP. For this purpose, we used boc-protected glutamic acid and 
coupled it to 4-azidobenzoic succinimidyl ester to generate azide derivatized boc 
glutamate. Later, we coupled photocaged doxorubicin with an azide unit via click 
chemistry to yield photocaged drug-dicarboxylate ligand. Later, our collaborators will use 
this drug conjugate to be attached to UCNP and demonstrate NIR mediated photorelease 
of the drug from the conjugate.  
Future studies: 
The ultimate aim of this project is to extend the usage of the photocaged drug delivery 
toward in vivo studies. The current established method is dependent on UV light, which 
does not penetrate deep into tissues. Hence, in this project we aim to demonstrate drug 
release using UCNPs that generate UV when irradiated with NIR and test it initially in 
vitro and later in vivo.   
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4.5. Experimental Section 
General 
All reagents were purchased from Sigma-Aldrich, Fisher Scientific, TCI or Chem-impex 
unless otherwise specified and were used as received. All reactions were carried out in 
oven dried glassware and under Ar or N2 atmosphere. The reactions were carried out in 
foil-wrapped flasks, protected from light. Flash chromatography was performed using 
Flash Silica Gel (32-63μ). 1H NMR/ 13C spectra were recorded on 400 MHz Bruker 
AVANCE instruments. HPLC purification was carried out using a Shimadzu Prominence 
system using Vydac (218TP C18 5μ) column using 0.1% TFA in acetonitrile and water 
as eluents and was monitored at λmax = 480 nm. M/S data was collected using Micromass 
MALDI-R/TOF (positive modes) unless mentioned.  
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4.6 Chemical Synthesis 
Synthesis of Photocaged doxorubicin has already been described in the experimental 
section of Chapter 2. 
Synthesis of di-tert-butyl 2-(4-azidobenzamido)pentanedioate (4.2): 
 
 
 
 
To a stirred solution of 6-azidobenzoic-OSu (2.8) (261 mg, 1 mmol, 1 eq.) in DMF (10 
mL) was added L-glutamate di-tert-butyl ester hydrochloride (338 mg, 1.3 mmol, 1.3 
eq.). and triethylamine (278 μL, 2 mmol, 2 eq.). The reaction was allowed to stir in the 
dark for 12 h. After this, DMF was removed in vacuo and the crude reaction mixture was 
diluted with CH2Cl2 and washed with 1 N aq. HCl. and then with brine. The organic layer 
was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to 
give a pale white solid, which was further purified via flash chromatography using a 
mixture of ethyl acetate and hexanes (1:1) to yield 320 mg (85%) of 4.2. 
1
H NMR (400 MHz, CDCl3) δ = 7.83 (2H, m, Ar-H), 7.07 (2H, m, Ar-H), 7.00 (1H, m,), 
4.65 (1h, , -CH-), 2.01-2.26 (2H, m, -CH2-), 2.28-2.47 (2H, m -CH2-), 1.49 (9H, s, Boc), 
1.42 ( 9H, s, Boc ). 
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13
C NMR (100 MHz, CDCl3) δ = 172.73, 171.32, 166.06, 143.51, 130.44, 128.96, 
118.96, 82.47, 80.96, 53.03, 31.71, 28.07, 28.04, 27.34,  
Synthesis of 2-(4-azidobenzamido) pentanedioic acid (4.3): 
 
 
 
 
100 mg of 4.2 was solubilized in a solution of 20% TFA in DCM (10ml) and stirred for 
~10 h in a foil-wrapped flask. The solvents in the reaction mixture were removed in 
vacuo.  To the pale colored oily solid, about cold ether (25 mL) was added.  The 
suspension was vortexed for about 5 minutes and then centrifuged in a 50 mL of falcon 
tube. This procedure was a second time giving yield the product as a brown colored oil 
70% yield (50 mg). 
1
H NMR (400 MHz, CDCl3) 
12.38 (2H, brs,-COOHx2), 8.62 (1H, d, J = 7.6 Hz, CONH), 7.95 (2H, m, Ar-H), 7.22 
(2H, m, Ar-H), 4.93 (m, 1H,-CH-), 2.36 (2H, 7.2 Hz, -CH2-), 2.09 (1H, m, -CH2-), 1.96 
(1H, m, -CH2-). 
13
C NMR (100 MHz, CDCl3) 
 δ = 173.78, 173.30, 165.59, 142.46, 130.44, 129.34, 118.82, 64.86, 51.95, 30.37, 25.90, 
15.10 
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Synthesis of 2-(4-azidobenzamido) pentanedioic acid (4.4): 
 
 
 
 
 
Compounds 2.13 (20 mg, 0.022 mmol, 1eq.) and 4.3 (13 mg, 0.044 mmol, 2 eq.) were 
stirred in 1:1 mixture of water and DMSO (2 mL each). 40 μL (0.4 mg, 0.002 mmol, 0.1 
eq.) of a freshly prepared aqueous solution of sodium ascorbate (10 mg/mL) was added to 
the reaction, followed by 4 μL (0.05 mg, 0.01 eq., 0.0002 mmol) of freshly prepared 
aqueous solution of copper (II) sulfate pentahydrate (12.5 mg/ mL), and finally 1.1 mg 
(0.1 eq., 0.002 mmol) of TBTA (Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine) was 
added. The red colored heterogenous mixture was stirred vigorously until the reaction 
was completed (~24h) as judged by TLC (1: 4 CH3OH/CHCl3). The reaction mixture was 
concentrated in vacuo, filtered and the resulting solution was purified on RP-HPLC using 
isocratic elution of 20 % organic eluent (0.1 % TFA in acetonitrile) for 5 minutes and 
then increasing the acetonitrile fraction in gradient fashion from 20 % to 100% over 30 
minutes at 10 ml/min. The fractions (~10 mL each) were collected into tubes containing 
1000 μL of ammonium bicarbonate (6 mg/ mL) solution to quench the TFA. The two 
diastereomers eluted between 20 and 22 min.  The fractions containing the diastereomers 
were evaporated leaving a red solid in ammonium bicarbonate. 
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Photocaged drug -
carboxylate ligand 
conjugate 
Dox-propargylamine 
Dox-propargylamine 
Fig. 4.5: HPLC chromatogram to show the formation of new diastereomeric peaks 
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Abstract:  
A new reaction-based fluorescent reporter for H2S has been developed based on 8-
aminopyrene-1, 3, 6-trisulfonate. This chapter describes a probe that has high selectivity 
for H2S over other ions and thiols, and can detect H2S directly in serum without additives. 
5. 1. Introduction 
Although previously considered as a toxic gas, hydrogen sulfide has recently been 
discovered to be an important gaseous signaling compound. H2S has been shown to be 
involved in a diverse and ever expanding array of biochemical processes such as 
inflammation, control of blood pressure, neurotransmission, and ischemia reperfusion.
1–9
 
Several methods to determine the H2S concentration in biological samples have been 
developed including those based on colorimetric,
10,11
 electrochemical,
12,13
 and other 
approaches.
14, 15 
However, these methods often require extensive sample processing 
before measurement, complicating their use.  
Because of the potential ability to monitor H2S in situ, we and other groups have very 
recently become interested in investigating the use of fluorescence-turn-on reporters for 
H2S.
16–29
 One successful strategy pioneered by the Chang group
19
 has been to use the 
ability of H2S to rapidly and selectively reduce azides to amines as a means to turn on 
fluorescence.
22,23,26,29
 Conveniently, many fluorescent molecules are quenched when their 
aryl amino groups are converted to the corresponding azides.
29–31
 In this chapter, our 
effort has focused on an azido analog of 8-aminopyrene-1,3,6-trisulfonic acid (APTS) 
and its use as an H2S chemodosimeter (Fig. 5.1). As compared to other profluorescent 
molecules used for H2S sensing, 8-azidopyrene-1, 3, 6-trisulfonic acid (N3-PTS) has the 
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advantages of high selectivity vs. other ions and thiols, and extremely high water 
solubility. These features enable analysis of H2S concentrations in biological samples 
without prior sample processing. 
 
 
 
 
 
 
 
  
Fig: 5.1: N3-PTS, a highly water soluble chemodosimeter for measurement of H2S in biological 
fluids 
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5. 2. Design and chemical synthesis of the probe  
Our general strategy for detection of H2S in biological samples was based on usage of a 
water soluble molecule that carried an azide functional group, which renders it non-
fluorescent, and when converted to the amine functional group in presence of H2S, the 
fluorescence of molecule is restored (Fig. 5.1). To achieve this goal, we converted the 
highly water soluble and fluorescent dye, APTS, to the azido derivative, N3-PTS. 
Chemical Synthesis 
The chemical synthesis of the chemodosimeter probe proceeded according to Scheme 1. 
We first prepared APTS 5.2 from amino pyrene 5.1 (TCI America) by treating it with 
oleum in the presence of sodium sulfate 
34
. This reaction mixture was purified using flash 
chromatography and desalted using a Biogel-P2 column, eluting in 50 mM ammonium 
bicarbonate buffer.  APTS was treated with sodium nitrite in the presence of sulfuric acid 
to form the diazonium salt of pyrene trisulfonic acid, which was directly converted to N3-
PTS 5.3, with sodium azide. The resulting product was readily purified using size 
exclusion chromatography with Bio-Gel P-2 using ammonium bicarbonate buffer. The 
ammonium salt of N3-PTS is highly soluble in water at concentrations >100 mM.  
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Scheme to synthesize H2S detection probe 
 
 
 
 
 
 
 
 
Scheme 
5.1: Synthesis of N3-PTS from Aminopyrene 
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5. 3. Spectral Characteristics: 
The absorption spectrum of N3-PTS shows a blue-shift relative to APTS (Fig. 5.2 A) with 
peaks at 382 and 403 nm, vs. 427 nm for APTS. As seen with other fluorophores,
19,22,30,31
 
the presence of the azide dramatically quenches the fluorescence (Fig. 5.2 B) of N3-PTS.  
Relative quantum yield measurements:  
For the measurement of quantum yield, we plotted absorbance vs. integrated fluorescence 
λex=425 nm for solutions of APTS and N3PTS.  A comparison of the slopes of the lines 
shows that at 425 nm excitation, the quantum yield of N3-PTS is 24-fold lower than 
APTS (Fig. 5.3).   
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Fig. 5.2: Spectral parameters of APTS and N3-PTS. 
(A) The absorbance spectral scans of N3-PTS (red) and APTS (blue), both at 50 µM, are 
shown.  (B) The fluorescence spectral emission scans (λex = 435 nm) of N3-PTS (red) and 
APTS (blue), both at 5 μM, are shown. 
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Fig. 5.3: Relative quantum yield measurement of APTS and N3-PTS. Fluorescence 
spectra were obtained with λex = 425 nm. 
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Absorbance vs. Concentration plots 
In order to determine the wavelength for maximum fluorescence enhancement of APTS 
vs. N3PTS, we measured the extinction coefficients at 382, 424, 436, and 451 nm (see 
Fig. 5.3 and Table 5.1).  435 nm showed the maximal 42-fold increase in extinction 
coefficient, and this wavelength was therefore used to maximize fluorescent enhancement 
in the subsequent studies. 
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Fig. 5.4: Absorbance vs. concentration plots of APTS and N3-PTS at various wavelengths 
in water. 
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Table 5.1: Absorbance parameters were calculated using Beer’s law. 
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5. 4. Fluorescence enhancement is dependent on H2S concentration 
We expected that H2S-mediated azide reduction would convert N3-PTS to APTS, with a 
corresponding enhancement in fluorescence. A solution of 50 µM NaHS was prepared 
and added to 100 µM N3-PTS in phosphate buffer. The reaction was monitored by 
fluorescence (Fig. 5.5) and was compared with the same reaction lacking NaHS. A time-
dependent large increase in fluorescence was observed in the solution containing NaHS. 
After 90 minutes a 7-fold fluorescence enhancement was observed. 
Time Course of H2S reactions at different concentrations: 
We then monitored the concentration dependence of the H2S reaction with N3-PTS.  
Solutions of NaHS (0-100 M) were prepared and mixed with N3-PTS.  We then 
monitored the reaction in a fluorescence spectrometer at 505 nm at λex = 435 nm. We 
found that the fluorescence intensity of all solutions increased over time. The amount of 
the increase is proportional to the NaHS concentration (Fig. 5.6). 
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. 
 
Fig. 5.5:  Enhancement in fluorescence of N3-PTS solutions in the presence of H2S.  A 
solution of 100 μM N3-PTS and either 50 µM NaHS or water was incubated in phosphate 
buffer (pH 7.8) at room temperature for various times.  Fluorescence emission scans (λex 
= 435 nm) were taken every 5 minutes. 
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Fig. 5.6: Reaction of H2S at various concentrations with N3-PTS. The reaction was 
monitored at 505 nm (λex = 435 nm), and readings were taken at 1 minute intervals 
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5. 5. Selectivity of chemodosimeter towards H2S 
We then proceeded to test the selectivity of our potential H2S chemodosimeter versus a 
collection of several common anions, reactive oxygen and nitrogen species, and thiols 
(Fig. 5.7). Significant fluorescence enhancement was observed only in the presence of 50 
µM HS
−
. The fluorescence signal of other ions (OAc
−
, N3
−
, HCO3
−
, Cl
−
, OH
−
, NO2
−
, 
SO4
2−
, SO3
2−
, S2O3
2−
), thiols (glutathione and cysteine), or reactive oxygen and nitrogen 
species (Fig. 5.8) gave little to no fluorescence enhancement when tested at 1 mM, a 20-
fold higher concentration. Thus, N3-PTS shows excellent selectivity for aqueous 
hydrogen sulfide in the presence of other ions and thiols encountered in biological 
environments. 
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Fig. 5.7: Comparison of the fluorescence of N3-PTS after incubation in 50 mM phosphate 
buffer (pH 7.8) along with NaHS (50 mM) or NaOAc,NaN3, NaHCO3, NaCl, NaOH, 
NaNO2, Na2SO4, Na2SO3, Na2S2O4, reduced glutathione or L-cysteine hydrochloride (all 
1 M). Fluorescence emission (λex= 435 nm) was measured after 90 min. 
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Fig. 5.8: Comparison of the fluorescence of N3-PTS after incubation in 50 mM phosphate 
buffer (pH 7.8) along with with NaHS (50 μM) or NaOCl, Sodium Diethylamine 
NONOate, or tBuOOH (all 1 mM). Fluorescence emission (λex = 435 nm) was measured 
after 90 min. 
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In order to use N3-PTS to quantify HS
−
 in biological samples it is desirable that the 
fluorescence be linearly related to the sulfide concentration. Indeed, treatment of N3-PTS 
(100 µM) with several different concentrations of HS
−
 led to the expected linear 
relationship (Fig. 5.9). HS
−
 was easily quantifiable by fluorescence when its 
concentration was between 2 and 100 µM. 
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Fig. 5.9: Plot of H2S concentration vs. N3-PTS fluorescence. N3-PTS (100 mM) and H2S 
(0–100 mM) were incubated in 50 mM phosphate buffer pH 7.8 at room temperature for 
90 minutes. Error bars denote one standard deviation from the mean of three experiments. 
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5. 6. Detection of fluorescence in biological samples 
With the linearity and selectivity studies completed, we turned our attention H2S 
detection in biological milieu. First, we investigated the extent to which APTS 
fluorescence was quenched in fetal bovine serum (FBS) vs. standard phosphate buffer. 
FBS showed little, if any, quenching (Fig. 5.10) suggesting that the measurement of H2S 
could be accomplished directly in the media without prior removal of proteins. Moreover, 
the high water solubility of N3-PTS could in principle allow measurement of fluorescence 
without addition of any organic co-solvents or detergents. We then titrated NaHS into 
FBS containing N3-PTS. After 90 minutes, the fluorescence was measured showing good 
linear dependence (Fig. 5.11).The point at which the fluorescence was >2-fold above 
background was 9 µM. 
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Fig. 5.10: Comparison of fluorescence intensity (λex = 450 nm) of APTS at various 
concentrations in either phosphate buffer or Serum (FBS). 
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Fig. 5.11: Linear relationship between H2S concentration and N3-PTS fluorescence in 
90% fetal bovine serum (FBS). N3-PTS (100 mM) and H2S (0–100 mM) were incubated 
in FBS at room temperature for 90 minutes. Error bars denote one standard deviation 
from the mean of three experiments. 
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Using N3-PTS, we can measure the H2S concentration in FBS in the range of 10–100 µM. 
This concentration range corresponds exactly with the range of H2S concentrations found 
in human blood.
32
 We also observed that the fluorescence enhancement in FBS at the 
same concentration of NaHS was diminished compared to phosphate buffer. This reduced 
sensitivity was presumably due to the quenching of the added HS
−
 with serum 
electrophiles.
33
 We surmise, therefore, that derivatizing N3-PTS to maximize its reaction 
rate with H2S will lead to enhanced sensitivity in serum. 
5. 7. Summary 
In summary we have developed a new chemodosimeter for hydrogen sulfide based on 
H2S conversion of profluorescent N3-PTS to APTS. N3-PTS can be prepared in good 
yield in a single step from commercially available APTS. N3-PTS shows very high 
selectivity for H2S and is extremely water soluble. These two properties have allowed us 
to measure H2S levels in serum directly without any processing of the sample or addition 
of detergents or co-solvents. The compatibility of N3-PTS with aqueous solutions 
distinguishes it from other fluorescent methods for H2S detection and makes it well suited 
for in situ analysis of H2S levels in a variety of biological fluids. 
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5. 8. Experimental section 
I. General 
All reagents were purchased from Sigma-Aldrich, Fisher Scientific or TCI America 
unless otherwise specified and were used as received. Reactions were carried out in foil-
wrapped flasks protected from light. Purification of the intermediates were carried out 
either using flash chromatography using Flash Silica Gel (32-63μ) or using a Biogel P-2 
column (1.5 x 80 cm), eluted with 50 mM aq. NH4OAc.  
Fluorescence spectra were recorded with a Cary Eclipse Fluorescence Spectrophotometer 
(Agilent Technologies, Inc.) at ambient temperature and under ambient atmosphere. 
Samples were contained in black, flat-bottomed 96 well plates. The PMT setting was 600 
V for all readings. For samples containing H2S, the plate was sealed immediately after 
addition of a NaHS solution of the appropriate concentration. Fluorescence readings were 
taken either with the seal removed or with optically clear sealing tape intact. Readings 
taken in FBS had a final FBS concentration of 90%, with the remaining 10% aqueous 
solution containing the fluorophore and NaHS. 
UV-Vis Absorbance spectra were recorded on a Hewlett Packard 8453 UV-visible 
Spectroscopy Systems instrument in disposable UV cuvettes (BrandTech) (Quantum 
yield measurements) or using a Nano-Drop 2000 spectrophotometer (UV-Vis absorbance 
profile and Beer’s Law readings). IR readings were taken on a Nicolet Avatar 360 FT-IR. 
1
H NMR spectra were recorded on a Bruker 400 MHz NMR and were calibrated to the 
D2O solvent peak which was set to 4.79 ppm. 
13
C NMR spectra were recorded on a 600 
MHz Bruker Advance III instrument using the attached proton test. 
13
C NMR spectra in 
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D2O were calibrated using methanol as an internal standard set to 49.50 ppm. Even using 
this high field instrument there were indistinguishable 
13
C peaks for N3-PTS. Observed 
peaks were reported. Mass spectra were acquired on a LTQ-Orbitrap Velos from Thermo 
Electron Corporation operating in negative ion mode. 
171 
 
5.9. Chemical synthesis 
Synthesis of Aminopyrene trisulfonic acid trisodium salt (APTS), (5.2): 
 
A dry round bottom flask with Na2SO4 (1.13 g, 8 mmol, 4 eq.) and conc. H2SO4 (5 mL) 
was arranged for reflux and fitted with a drying tube (filled with drierite and NaOH 
pellets). Aminopyrene (434 mg, 2 mmol, 1 eq.) was added along with fuming sulfuric 
acid (20%, 6 mL). The mixture was stirred for ~1.5 days at 60
0
C and monitored using 
TLC (NH4OH: IPA, 1:2). After the completion of the reaction, the mixture was quenched 
using 50% NaOH and the pH is brought up to about 7. Later the solvents were removed 
in vacuo and the mixture was diluted with methanol, filtered to remove salts and purified 
using flash column using 1: 2 ratio of NH4OH and Isopropyl alcohol leaving 1.0 g of a 
yellow solid.  534 mg of this solid was purified in two portions using Biogel P-2 
chromatography (1.5 x 90 cm column, eluting with 50 mM NH4HCO3 at 0.15 mL/min).  
Fractions containing the product were combined and lyophilized leaving 174.2 mg of an 
orange solid. 
Yield:  ~1gm (98% yield) sodium salt; 174 mg from 534 mg of sodium salt (33 % yield)  
1
H NMR (D2O, 400 MHz): 9.29 (s, 1H), 9.14 (d, 1H, J = 16 Hz), 9.035 (d, 1H, J = 12 
Hz), 8.90 (d, 1H, J = 12 Hz), 8.42 (d, 1H, J = 16 Hz), 8.17( s, 1H). 
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Triammonium 8-azidopyrene-1, 3, 6-trisulfonate (N3-PTS), (5.3): 
 
A solution of triammonium 8- aminopyrene-1,3,6-trisulfonate (100 mg, 0.22 mmol) was 
dissolved in ice cold 3.6 N H2SO4 (500 μL) in a foil wrapped flask on ice. An aqueous 
solution of 0.66 M NaNO2 (1 mL, 3 eq) was added dropwise over 10 min. A solution of 
ice cold 1.1 M sodium azide (1.2 mL, 6 eq) was added dropwise over 10 min. The 
reaction was stirred on ice for an additional 40 min and was quenched with 0.5 mL 
concentrated NH4OH. The solution was concentrated via rotary evaporation and purified 
using a Biogel P-2 column (1.5 x 80 cm), eluting with 50 mM aq NH4HCO3 at a flow rate 
of 0.15 mL/min. The fractions containing the product were combined and lyophilized 
giving a fluffy yellow powder (79 mg, 75%).    
IR νmax/cm
-1
 (3435m, 3180s, 3199s, 2870m, 2113s (N3 stretch), 1625w, 1416s, 1161s, 
1115s, 1036s, 998s, 733m, 653s, 604s).  
1
H NMR (400 MHz, D2O): δ = 9.23 (s, 1H), 9.21 (d, 1H, J = 9.8 Hz), 9.11 (d, 1H, J = 9.8 
Hz), 9.10 (d, 1H, J = 9.7 Hz), 8.73 (d, 1H, J = 9.7 Hz), 8.64 (s, 1H). 
13
C NMR (150 MHz, D2O): δ = 139.05 (q), 135.90 (q), 130.43 (q), 129.71 (q), 127.73 (C-
H), 125.68 (C-H), 125.51 (q), 125.20 (C-H), 124.87 (C-H), 124.76 (C-H), 123.44 (q), 
123.40 (q), 116.60 (C-H).  
HRMS (ESI) C16H7N3O9S3 calculated [M – 2H] 
2-
 = 240.4677; Observed = 240.4678. 
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Fig. 4.5: HPLC chromatogram to show the formation of new diastereomeric peaks between 20 
and 22 mins. Dox propargylamine (2.13) is seen between 22-24 mins. 
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